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Introduction {#sec1}
============

During central nervous system (CNS) development, the formation of neuronal synapses at the right time, in the right place, and of the right strength is crucial to the ongoing function of the brain throughout life. Work in recent years has shown that secreted signals from neighboring astrocytes strongly regulate synapse formation, affecting not only when and where synapses would form, but also whether an active or a silent synapse will develop ([@bib1], [@bib54]). Silent synapses are induced by astrocyte-secreted thrombospondins and hevin, each regulating distinct molecular pathways in neurons ([@bib11], [@bib18], [@bib31], [@bib48]). We previously showed that astrocyte-secreted glypicans 4 and 6 (Gpc4 and Gpc6) induce active synapse formation by recruiting dendritic GluA1-containing AMPA glutamate receptors (AMPARs) ([@bib2]); however, the neuronal signaling pathways that underlie this effect have not been determined. Here we identify the signaling pathway induced in neurons by astrocyte-secreted Gpc4, leading to functional synapse formation.

GluA1, the AMPAR subunit regulated by Gpc4 and Gpc6, is a major component of AMPARs at developing synapses, suggesting an important role for Gpc4 in synapse initiation ([@bib2]). It has been proposed that, in developing neurons, AMPARs are present at nascent synaptic contacts but in an unstable state and that the stabilization of AMPARs is crucial for the maintenance and maturation of these synapses ([@bib22]). A major way of regulating synaptic AMPAR stability and function is via AMPAR-interacting proteins that can act both intra- and extracellularly ([@bib4], [@bib23]). An important family of extracellular regulators are the neuronal pentraxins (NP): NP1, NP2 (also known as NARP), and NPR ([@bib34], [@bib40], [@bib46], [@bib57], [@bib59]). These secreted glycoproteins bind to AMPARs and stabilize them on dendritic surfaces ([@bib40]). Removal of all NPs from developing neurons leads to severe delays in active synapse formation *in vitro*, and loss of neuronal pentraxins *in vivo* causes defects in synapse maturation and in the activity-dependent refinement of circuits ([@bib5], [@bib30], [@bib46]). NP1 is most highly expressed in the developing brain when synapses are first forming ([@bib5]). In contrast to NP2, which is an immediate early gene whose mRNA is known to be regulated by neuronal activity ([@bib59]), the mechanisms that regulate release of NP1 from neurons are not known.

Type 2a receptor protein tyrosine phosphatases (RPTPs) and leucine-rich repeat transmembrane proteins (LRRTMs) can act as neuronal receptors for glypican family members, but whether they mediate the effects of astrocyte-secreted Gpc4 is unknown ([@bib12], [@bib14], [@bib26], [@bib29], [@bib47], [@bib49]). Postsynaptic LRRTM3 and LRRTM4 interact with a neuronal membrane-tethered Gpc4 via *trans*-synaptic binding to regulate synapse formation ([@bib14], [@bib29], [@bib47]). Presynaptic RPTPs interact with glypicans to regulate axon extension ([@bib12]) and promote synapse formation via *trans*-synaptic interaction with surface receptors and cell adhesion molecules ([@bib13], [@bib16], [@bib50], [@bib49]). Mice lacking RPTPs or LRRTMs show deficits in synapse formation, making them strong candidates for mediating the actions of astrocyte-secreted Gpc4 ([@bib24], [@bib38], [@bib47], [@bib52]). Importantly, the mechanism of how synapses are formed downstream of Gpc4-receptor interaction is not known.

Here we identify the pathway of astrocyte-secreted Gpc4 in inducing functional synapse formation. We found that Gpc4 induces release of the AMPAR-clustering factor NP1 from axons by interacting with presynaptic RPTPδ. The secreted NP1 binds and recruits postsynaptic GluA1-containing AMPARs, promoting active synapses to form. Our findings reveal a functional link between pre- and postsynaptic signaling pathways and provide important mechanistic insight into the role of astrocytes in neuronal synaptogenesis. Mutations in glypican family members have been implicated in multiple neurological disorders that have underlying synaptic dysfunction, including autism spectrum disorder (ASD), attention-deficit hyperactivity disorder (ADHD), and schizophrenia ([@bib15], [@bib35], [@bib43]). Identification of the molecular mechanism of how glypicans regulate synapse formation, and their unexpected functional link with NP1, opens new avenues to explore the mechanisms of these disorders.

Results {#sec2}
=======

Glypican 4 Regulates Neuronal Expression of Genes Related to AMPAR Synaptic Localization {#sec2.1}
----------------------------------------------------------------------------------------

Due to the relatively slow effect of Gpc4 on GluA1 synaptic expression ([@bib2]), we hypothesized that Gpc4 regulates neuronal signaling pathways that mediate AMPAR dendritic clustering. To test this, we took an unbiased approach---gene expression profiling of neurons treated with soluble Gpc4 protein to mimic the astrocyte-secreted form, using pure cultures of retinal ganglion cell neurons (RGCs) ([@bib54]). RGCs are ideal for these studies as they form few synapses when cultured in isolation but profoundly increase synapse number and function when cultured with astrocytes or astrocyte-secreted proteins, including Gpc4 ([@bib2]). RGCs were treated for 12 hr (preceding the surface GluA1 increase; [@bib2]) with Gpc4 to induce active synapse formation or thrombospondin 1 (TSP1) to induce silent synapse formation ([Figure 1](#fig1){ref-type="fig"}A), and mRNA levels were measured using microarrays. TSP1 is an additional control as it induces structurally intact, but functionally silent, AMPAR-lacking synapses by signaling through the α2δ1 receptor ([@bib11], [@bib18]), so it is not predicted to use the same mechanism as Gpc4. There was no overlap in gene expression changes induced by Gpc4 (49 genes) and TSP1 (3 genes), highlighting that they induce synapse formation via distinct pathways ([Table S1](#mmc2){ref-type="supplementary-material"}). We focused on factors known to regulate synaptic clustering of AMPARs and found that, interestingly, mRNA for neuronal pentraxin 1 (NP1) is significantly upregulated by Gpc4 treatment (1.83-fold, [Table S2](#mmc1){ref-type="supplementary-material"}).Figure 1Gpc4 Upregulates Release of the AMPAR Clustering Factor NP1 from RGC Neurons(A) Model of experiment: RGCs were cultured alone or with Gpc4 to induce AMPARs containing active synapses or with TSP1 to induce AMPARs lacking silent synapses.(B) Diagram: Gpc4-induces presynaptic release of NP1, with NP1 binding to postsynaptic AMPARs and inducing synapse formation.(C and D) RGCs treated with ACM or Gpc4 for 6 days show increased surface accumulation of NP1. (C) Example images: green surface NP1, red labels whole cell. Inset shows enlarged dendritic region from box, surface NP1 white. (D) Quantification of (C), number of surface NP1 puncta per RGC normalized to Alone condition, n = 3 experiments.(E and F) TSP1 does not increase surface NP1. (E) Example images: as in (C). (F) Quantification of (E), number of surface NP1 puncta per RGC normalized to Alone condition, n = 4 experiments.(G--J) Time course of surface accumulation of NP1 in response to ACM or Gpc4 treatment for 4 or 12 hr. (G and H) Example dendrite images, green surface NP1, red labels whole process; below single channel NP1, white. (I and J) Quantification of (G) and (H), number of surface NP1 puncta per RGC normalized to Alone condition, n = 6 experiments 4 hr, 3 experiments 12 hr. Scale bars, 10 μm. Arrowheads mark example puncta of NP1. Graphs show mean ± SEM, number of cells per group inside the bar. ^∗^p ≤ 0.05, by t test when comparing two groups or one-way ANOVA when comparing three or more groups.See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

Glypican 4 Upregulates Release of the AMPAR Clustering Factor NP1 from Neurons {#sec2.2}
------------------------------------------------------------------------------

NP1 binds the extracellular region of AMPARs and clusters them on dendritic surfaces increasing synapse number ([@bib40], [@bib59]). This same effect is seen in neurons treated with soluble Gpc4 ([@bib2]), making regulation of NP1 an ideal candidate for Gpc4-induced synaptogenesis. Since NP1 is a secreted protein that acts in the extracellular space, we first asked whether Gpc4 would increase NP1 protein secretion ([Figure 1](#fig1){ref-type="fig"}B). RGCs were treated with soluble Gpc4 for 4 days, and levels of NP1 in the neuron culture media were assayed by western blot. Gpc4 treatment caused a significant increase in the extracellular levels of NP1 (2.07-fold ± 0.10-fold), and to a lesser extent NP2 (1.41-fold ± 0.10-fold; [Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B), showing that Gpc4 is sufficient to upregulate NP1 release from neurons. To determine whether secreted NP1 is binding to the surface of neuronal processes, which is necessary for it to cluster AMPARs ([@bib59]), we examined the levels of NP1 using a surface immunostaining assay. Treating RGCs with astrocyte conditioned media (ACM) or purified soluble Gpc4 for 6 days increased the amount of NP1 accumulated on the surface of neuronal processes by 1.54-fold ± 0.16-fold and 1.84-fold ± 0.22-fold for ACM and Gpc4, respectively ([Figures 1](#fig1){ref-type="fig"}C and 1D). The same results were obtained using two different antibodies against NP1 ([Figures S1](#mmc1){ref-type="supplementary-material"}C--S1F). To test the specificity of this effect, we treated RGCs with TSP1 to induce silent synapses that lack AMPARs ([Figure 1](#fig1){ref-type="fig"}A). TSP1 treatment did not increase surface levels of NP1 over untreated controls (1.18-fold ± 0.11-fold, ns; [Figures 1](#fig1){ref-type="fig"}E and 1F), showing that NP1 release is specific to the Gpc4 pathway.

To determine when an increase in NP1 surface accumulation can first be detected, we performed a time course experiment. At all times tested, both ACM and Gpc4 caused an increase in surface NP1 compared to untreated neurons. Measurements were performed at 4 hr (ACM: 1.72-fold ± 0.17-fold; Gpc4: 1.64-fold ± 0.15-fold), 12 hr (ACM: 2.10-fold ± 0.22-fold; Gpc4: 1.87-fold ± 0.26-fold), and 6 days (above) ([Figures 1](#fig1){ref-type="fig"}C, 1D, and 1G--1J). Because increases in NP1 surface accumulation preceded our 12-hr microarray time point, we used qRT-PCR to determine when a significant change in NP1 mRNA is detected. We found that NP1 mRNA was beginning to be upregulated compared to untreated RGCs after 4 hr (1.28-fold ± 0.27-fold, ns) and significantly upregulated after 12 hr (1.23-fold ± 0.07-fold) and 18 hr (1.56-fold ± 0.11-fold), but not after 1 hr (1.09-fold ± 0.06-fold, ns) ([Figure S1](#mmc1){ref-type="supplementary-material"}G). Gpc4 treatment did not alter the mRNA expression levels of the other NPs (NP2 and NPR) at any time point assayed ([Figure S1](#mmc1){ref-type="supplementary-material"}G). To determine whether an increase in NP1 mRNA is necessary for the increase in surface accumulation of NP1 protein ([Figures 1](#fig1){ref-type="fig"}C, 1D, and 1G--1J), we treated RGCs with actinomycin D (ActD) to block mRNA synthesis, and asked whether Gpc4 was still able to increase surface NP1, assayed by immunostaining. ActD had no effect on the ability of Gpc4 to increase surface NP1 after 4 hr (Gpc4: 2.54-fold ± 0.27-fold; Gpc4+ActD: 2.32-fold ± 0.21-fold) ([Figures S1](#mmc1){ref-type="supplementary-material"}H and S1J), but it blocked the increase in NP1 following 12 hr of Gpc4 treatment compared to untreated RGCs (Gpc4: 2.05-fold ± 0.24-fold; Gpc4+ActD: 0.81-fold ± 0.07-fold; [Figures S1](#mmc1){ref-type="supplementary-material"}I and S1K). These results demonstrate that the initial step of Gpc4-induced synaptogenesis is increasing secretion and surface accumulation of NP1 protein, rather than regulation of NP1 mRNA levels, suggesting that a local synaptic signaling mechanism may initiate NP1 protein secretion. This possibility is explored in the following experiments.

Interaction between NP1 and GluA1 Is Necessary for Glypican 4 to Induce Synapse Formation {#sec2.3}
-----------------------------------------------------------------------------------------

We previously demonstrated that surface clustering of GluA1 is necessary for Gpc4 to induce synapse formation ([@bib2]). NP1 induces synapse formation by binding to AMPARs ([@bib34], [@bib59]), so we next asked whether blocking the NP1-GluA1 interaction would prevent Gpc4-induced synaptogenesis. To do this, we generated a Fab antibody fragment that specifically binds the amino-terminal domain (ATD) of GluA1 (GluA1-Fab), the NP1 binding site, but not to other AMPAR subunits ([Figure 2](#fig2){ref-type="fig"}A). Specific binding was confirmed by surface plasmon resonance analysis ([Figure 2](#fig2){ref-type="fig"}B) and by immunostaining HEK293T cells overexpressing different AMPAR subunits with GluA1-Fab, showing binding to GluA1, but not GluA2, GluA3, or GluA4, ([Figure S2](#mmc1){ref-type="supplementary-material"}A). As a control, we mutated the GluA1-Fab CDR region, generating the Mut-Fab variant, which does not bind GluA1 ([Figure S2](#mmc1){ref-type="supplementary-material"}B). To determine whether the GluA1-Fab can block NP1 binding to RGC processes, we applied recombinant NP1 labeled with Alexa 488 to RGCs *in vitro* for 24 hr, either by itself or in the presence of the Mut-Fab or GluA1-Fab. NP1-Alexa 488 showed robust binding to RGC processes ([Figure 2](#fig2){ref-type="fig"}C), and this was significantly decreased by the presence of the GluA1-Fab, whereas the Mut-Fab had no effect (Mut-Fab: 0.92-fold ± 0.05-fold; GluA1-Fab: 0.61-fold ± 0.05-fold; compared to NP1-Alexa 488: no treatment; [Figures 2](#fig2){ref-type="fig"}C and 2D). We next asked whether the GluA1-Fab could inhibit Gpc4-mediated synapse formation. RGCs were treated for 6 days with soluble Gpc4 along with the GluA1-Fab or the Mut-Fab ([Figure 2](#fig2){ref-type="fig"}A). Synapse formation was assayed by immunostaining for Bassoon (presynaptic active zone) and Homer (postsynaptic density), with colocalization of these markers counted as structural synapses ([@bib2], [@bib18]). The presence of the GluA1-Fab prevented synapse formation in response to Gpc4 (1.04-fold ± 0.15-fold; ns), whereas the Mut-Fab had no effect (2.18-fold ± 0.26-fold; [Figures 2](#fig2){ref-type="fig"}E and 2F).Figure 2NP1-GluA1 Interaction Is Necessary for Gpc4 to Induce Structural Synapse Formation(A) Diagram: Fab against the N-terminal domain of GluA1 (GluA1-Fab) prevents Gpc4-induced synapse formation.(B) Surface plasmon resonance analysis of GluA1-Fab specificity. GluA1-Fab binds GluA1 AMPAR N-terminal domain, but not GluA2, GluA3, or GluA4.(C and D) Recombinant NP1-Alexa 488 binds RGC dendrites, and GluA1-Fab disrupts this binding, Mut-Fab has no effect. (C) Example images of RGCs treated with NP1-Alexa 488 (green), red labels whole cell. Inset shows enlarged dendritic region from box, surface NP1 white. Arrowheads mark example puncta of NP1. (D) Quantification of (C), number of surface NP1-Alexa 488 puncta normalized to NP1-Alexa 488 no Fab group (None). n = 3 experiments.(E and F) Treating RGCs with GluA1-Fab blocks Gpc4-mediated synapse formation. (E) Example images of RGCs, red Bassoon, green Homer. Inset shows enlarged dendritic region from box. Arrowheads mark example synapses (colocalized Bassoon-Homer puncta). (F) Quantification of (E), number of synapses per RGC normalized to Alone, n = 4 experiments.(G--J) Knockdown of NP1 by siRNA blocks Gpc4 effect on GluA1 surface clustering (G and H) and synapse formation (I and J). (G) Example images of RGC dendrites showing single-channel GluA1 puncta. Arrowheads mark example GluA1 surface puncta. (H) Quantification of (G), number of GluA1 puncta normalized to siControl+Alone. n = 4 experiments. (I) Example images of RGC processes stained for VGlut2 red, PSD95 green. Arrowheads mark example synapses (colocalized VGlut2-PSD95). (J) Quantification of (I), number of synapses per RGC normalized to siControl+Alone, n = 4 experiments. Scale bars, 10 μm. Graphs show mean ± SEM, number of cells per group inside the bar. ^∗^p ≤ 0.05, by one-way ANOVA.See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

As an alternative approach to determine necessity of NP1 for Gpc4-induced synapse formation, we used small interfering RNA (siRNA) to knock down NP1 expression in RGCs. Transfection of RGCs with siNP1 caused a significant 76% decrease in surface accumulation of NP1 protein compared to a non-targeting siControl ([Figures S2](#mmc1){ref-type="supplementary-material"}C and S2D), confirming the efficacy of the siRNA. We then asked whether soluble Gpc4 was able to increase surface clustering of GluA1 in RGCs transfected with siNP1 compared to siControl by immunostaining using an antibody specific for the extracellular region of GluA1 ([@bib2]). Transfection of RGCs with siNP1 prevented Gpc4-mediated increase in surface GluA1 (0.99-fold ± 0.07-fold), whereas siControl did not (1.65-fold ± 0.08-fold; [Figures 2](#fig2){ref-type="fig"}G and 2H). Next, we asked whether RGCs transfected with siNP1 could form structural synapses in response to Gpc4 by immunostaining RGCs for vesicular glutamate transporter type 2 (VGlut2 - presynaptic vesicles) and PSD95 (postsynaptic density). Transfection of RGCs with siNP1 prevented Gpc4-mediated synapse formation (1.13-fold ± 0.09-fold), whereas the siControl did not (1.68-fold ± 0.11-fold; [Figures 2](#fig2){ref-type="fig"}I and 2J). These data demonstrate that soluble Gpc4 regulates synaptic recruitment of GluA1 and synaptogenesis by increasing the release of NP1, which binds GluA1 AMPARs to induce synapse formation. NP1 is released from presynaptic terminals ([@bib46]), suggesting that Gpc4 acts by interacting with a presynaptic receptor, an unexpected finding for an astrocyte-secreted factor that increases surface clustering of postsynaptic GluA1 AMPARs.

Presynaptic RPTPδ Mediates Glypican 4-Induced Synapse Formation {#sec2.4}
---------------------------------------------------------------

Previous work has identified type 2a RPTPs as potential presynaptic receptors for glypicans---specifically RPTPσ and LAR ([@bib12], [@bib26], [@bib29]). Rodent RGCs express mRNA for all three type 2a RPTPs: σ, δ, and LAR ([Table S3](#mmc1){ref-type="supplementary-material"}; [@bib6]), making them strong candidates for mediating the effect of astrocyte-secreted Gpc4 ([Figure 3](#fig3){ref-type="fig"}A). Due to potential functional redundancy between the RPTPs, we first asked whether overexpression of RPTPs *in vitro* would increase synapse formation in response to the putative ligand Gpc4. We first tested whether overexpression of RPTPs in the presynaptic compartment (i.e., axons) could enhance Gpc4-induced synapse formation ([Figure 3](#fig3){ref-type="fig"}B). Axons expressing each RPTP were identified by immunostaining for the hemagglutinin (HA)-tag (in the receptor), and synapses were stained with Bassoon and PSD95 ([Figure 3](#fig3){ref-type="fig"}C). Overexpression of LAR or RPTPσ in the axon did not enhance Gpc4-mediated synapse formation ([Figures 3](#fig3){ref-type="fig"}D--3G), although overexpression of RPTPσ was sufficient to increase synapse formation by itself in the absence of Gpc4 (1.65-fold ± 0.22-fold; [Figures 3](#fig3){ref-type="fig"}F and 3G). Overexpression of RPTPδ significantly increased synapse formation by itself (1.84-fold ± 0.25-fold; [Figures 3](#fig3){ref-type="fig"}H and 3I) and, importantly, further enhanced synapse formation in response to Gpc4 by 4.70-fold ± 0.56-fold ([Figures 3](#fig3){ref-type="fig"}H and 3I). We then asked whether overexpression of these receptors in the postsynaptic compartment (i.e., dendrites) could enhance Gpc4-induced synaptogenesis and found no significant effect ([Figure S3](#mmc1){ref-type="supplementary-material"}A). These data demonstrate that axonal RPTPδ, but not RPTPσ or LAR, is sufficient to mediate the synaptogenic effect of Gpc4.Figure 3Glypican 4 Acts through Presynaptic RPTPs to Increase Synapse Formation(A) Diagram: Gpc4 is acting through presynaptic RPTPs to induce synapse formation.(B and C) Schematic of experiment performed in (D)--(I). (B) RPTPs are overexpressed in the axon (green cell), and synapses (black dots) formed by that axon onto neighboring dendrites (blue cells) are analyzed. (C) Example experiment with Imaris rendering to demonstrate analysis of synapses formed by the transfected axon. Left: raw image---transfected axon green, Bassoon blue, PSD95 red. Scale bar, 10 μm. Middle: Imaris rendering of green axon with synapses within that axon (white spheres represent colocalized pre- and postsynaptic puncta). Right: zoom in of rendered axon from box. Scale bar, 2 μm.(D--I) Overexpression of RPTPδ in RGC axons enhances Gpc4-mediated synapse formation, no effect of RPTPσ, or LAR. (D, F, and H) Example images, axon green, Bassoon blue, PSD95 red. (E, G, and I) Quantification of (D), (F), and (H), respectively, synapse number per expressing axon normalized to GFP Alone group, n = 3 experiments each RPTP.(J--K) Altering RPTPσ or RPTPδ function with wedge peptides blocks Gpc4-mediated synapse formation. (J) Example process images, Bassoon red, PSD95 green. (K) Quantification of (J), synapse number per cell normalized to Alone no peptide group, n = 5 experiments.(L and M) Blocking RPTPσ with wedge peptides prevents TSP1-induced synapse formation, blocking RPTPδ has no effect. (L) Example images, Bassoon red, PSD95 green. (M) Quantification of (L), synapse number per cell normalized to Alone no peptide group, n = 3 experiments. Scale bars for (D)--(M), 10 μm. Arrowheads mark example synapses. Graphs show mean ± SEM, number of cells per group inside the bar. ^∗^p ≤ 0.05, by one-way ANOVA.See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

Blocking RPTP Interactions Prevents Glypican 4-Induced Synapse Formation {#sec2.5}
------------------------------------------------------------------------

We next asked whether RPTP function is necessary for Gpc4-induced synapse formation. To test this, we used cell-permeant wedge domain-blocking peptides to alter RPTPs' interactions with their downstream targets ([@bib58]). RPTPs are receptors for heparan sulfate proteoglycans (HSPGs), such as glypicans and chondroitin sulfate proteoglycans (CSPGs). CSPG-RPTP interactions inhibit axon outgrowth and block axon regeneration ([@bib12]). Wedge peptides block the RPTP-mediated inhibitory effect of CSPGs on axon growth, demonstrating their functional efficacy ([@bib33]). We asked whether peptides that specifically target RPTPσ, RPTPδ, or LAR, as well as a scrambled RPTPσ peptide, could block the synaptogenic actions of Gpc4. RGCs were treated with soluble Gpc4 for 6 days in the presence or absence of wedge domain-blocking peptides, and structural synapses were assayed by immunostaining for Bassoon and PSD95. The scrambled σ and LAR peptides did not affect Gpc4-induced synaptogenesis ([Figures S3](#mmc1){ref-type="supplementary-material"}B and S3C). However, treating RGCs with peptides against RPTPσ or RPTPδ prevented Gpc4-mediated synaptogenesis (Gpc4: 1.66-fold ± 0.14-fold; Gpc4 + scrambled peptide: 1.57-fold ± 0.14-fold; Gpc4 + δ peptide: 1.13-fold ± 0.14-fold; Gpc4 + σ peptide: 1.01-fold ± 0.13-fold compared to no Gpc4 treatment; [Figures 3](#fig3){ref-type="fig"}J and 3K). To determine the specificity of RPTP function for Gpc4-mediated synaptogenesis, we treated RGCs with TSP1 to induce silent synapse formation in the presence or absence of the blocking peptides. Blocking RPTPσ reduced synapse formation in response to TSP1 (TSP1: 2.19-fold ± 0.30-fold; TSP1 + σ peptide: 1.51-fold ± 0.24-fold compared to no TSP1 treatment), whereas blocking RPTPδ had no effect (TSP1 + δ peptide: 2.01-fold ± 0.29-fold; [Figures 3](#fig3){ref-type="fig"}L and 3M). This shows that RPTPδ is necessary for Gpc4-mediated synaptogenesis and is specific to this pathway, whereas RPTPσ is necessary for synaptogenesis induced by multiple astrocyte-secreted factors.

Blocking RPTP Interactions Prevents Glypican 4-Induced GluA1 Clustering {#sec2.6}
-----------------------------------------------------------------------

A crucial step in Gpc4-mediated synaptogenesis is the surface clustering of GluA1 AMPARs ([@bib2]), so we next asked whether RPTPδ or RPTPσ are involved in Gpc4-mediated GluA1 clustering ([Figure 4](#fig4){ref-type="fig"}A). RGCs were treated with Gpc4 and each blocking peptide, and surface clustering of GluA1 was measured by immunostaining. Blocking either RPTPσ or RPTPδ prevented the Gpc4-mediated increase in surface GluA1 (Gpc4: 2.30-fold ± 0.26-fold; Gpc4 + scrambled peptide: 1.97-fold ± 0.20-fold; Gpc4 + δ peptide: 1.13-fold ± 0.15-fold; Gpc4 + σ peptide: 1.34-fold ± 0.19-fold; each compared to no Gpc4 treatment; [Figures 4](#fig4){ref-type="fig"}B and 4C). These results demonstrate that presynaptic RPTPδ and RPTPσ are necessary for Gpc4 induction of GluA1 clustering in RGCs.Figure 4Glypican 4 Acts through Presynaptic RPTPs to Induce the Release of NP1 and to Cluster GluA1 AMPA Receptors(A) Diagram: Gpc4 binds to presynaptic RPTPδ to induce the release of NP1, which binds postsynaptic AMPARs to induce synapse formation.(B and C) Blocking RPTPσ or RPTPδ with wedge peptides prevents Gpc4-mediated surface clustering of GluA1. (B) Example images, GluA1 green, red labels whole cell. Inset shows enlarged dendritic region from box, surface GluA1 white. Arrowheads mark example clusters of GluA1. (C) Quantification of (B), number of GluA1 puncta per cell normalized to RGC alone no peptide group, n = 3 experiments.(D and E) Blocking RPTPσ or RPTPδ with wedge peptides prevents Gpc4-mediated surface accumulation of NP1. (D) Example images, NP1 green, red labels whole cell. Inset shows enlarged dendritic region from box, surface NP1 white. Arrowheads mark example puncta of NP1. (E) Quantification of (D), number of NP1 puncta per cell normalized to RGC alone no peptide condition, n = 3 experiments. Scale bars, 10 μm. Graphs show mean ± SEM, number of cells per group inside the bar. ^∗^p ≤ 0.05, by one-way ANOVA.

Blocking RPTP Interactions Prevents Glypican 4-Induced NP1 Surface Accumulation {#sec2.7}
-------------------------------------------------------------------------------

We have demonstrated that soluble Gpc4 increases the release and surface accumulation of NP1 from neurons ([Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}) and that Gpc4 acts through presynaptic RPTPδ and RPTPσ receptors to induce GluA1 clustering and synapse formation ([Figures 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}). To determine whether there is a functional link between these two pathways, we asked whether blocking RPTPδ or RPTPσ *in vitro* would prevent Gpc4-induced increases in NP1 surface accumulation ([Figure 4](#fig4){ref-type="fig"}A). RGCs were treated with Gpc4 and each blocking peptide, and surface levels of NP1 were measured using immunostaining. Inhibiting RPTPδ or RPTPσ prevented the Gpc4-mediated increase in NP1 surface accumulation ([Figures 4](#fig4){ref-type="fig"}D and 4E), linking together the RPTP and NP1 pathways.

Glypican 4 Is Expressed by Astrocytes throughout the Developing Visual System {#sec2.8}
-----------------------------------------------------------------------------

What is the importance of this astrocyte-regulated presynaptic signaling cascade to synapse formation *in vivo*? We examined this question in the developing mouse visual system, as our *in vitro* work was conducted on retinal ganglion cell neurons ([Figure S4](#mmc1){ref-type="supplementary-material"}D). We first confirmed that astrocytes are present in the visual system at postnatal day 6 (P6), when synapses are beginning to form ([@bib54]), using *in situ* hybridization (ISH) to detect mRNA for the astrocyte marker Aldh1l1 ([@bib7]). A strong signal for Aldh1l1 was observed in the superior colliculus (SC) and dorsal lateral geniculate nucleus (dLGN), target regions of RGC axons *in vivo* ([Figure 5](#fig5){ref-type="fig"}A; [Figure S4](#mmc1){ref-type="supplementary-material"}A). A similar signal was detected in the visual cortex (VC), a target of axons from the dLGN ([Figure S4](#mmc1){ref-type="supplementary-material"}A). No signal was detected using the negative control probe ([Figure 5](#fig5){ref-type="fig"}A; [Figure S4](#mmc1){ref-type="supplementary-material"}A, right). We then asked whether Gpc4 mRNA is expressed in these brain regions at P6. Gpc4 expression was detected in the SC, dLGN, and VC, and no signal for Gpc4 was detected in Gpc4 knockout (KO) mice ([Figure 5](#fig5){ref-type="fig"}B). To determine which cells express Gpc4 in these regions, we performed triple fluorescent ISH, combining Gpc4, an astrocyte marker (Aldh1l1), and a neuronal marker (Tubb3) ([Figures 5](#fig5){ref-type="fig"}C--5F; [Figures S4](#mmc1){ref-type="supplementary-material"}B and S4C). We focused on the superficial layers of the SC, a target region of RGCs, and layer 4 of the VC, a target region of dLGN projections ([Figures S4](#mmc1){ref-type="supplementary-material"}C and S4D). In the SC, we detected strong overlap between Gpc4 and Aldh1l1 and little overlap between Gpc4 and Tubb3 (fraction Gpc4+Aldh1l1 cells: 0.85 ± 0.01; Gpc4+Tubb3 cells: 0.15 ± 0.01; [Figures 5](#fig5){ref-type="fig"}C and 5D), with minimal signal detected for the negative control probe ([Figure S4](#mmc1){ref-type="supplementary-material"}B). KO of Gpc4 resulted in minimal Gpc4 signal and no change in Aldh1l1 or Tubb3 signals, suggesting that KO of Gpc4 does not disrupt neuron or astrocyte formation ([Figure 5](#fig5){ref-type="fig"}C, bottom). Similar triple ISH results were obtained in the VC, showing higher overlap of Gpc4 with Aldh1l1 than with Tubb3 (Gpc4+Aldh1l1 cells: 0.71 ± 0.03; Gpc4+Tubb3 cells: 0.29 ± 0.04; [Figures 5](#fig5){ref-type="fig"}E and 5F). This confirms previous work from other brain regions showing elevated levels of Gpc4 expression in developing astrocytes compared to neurons ([@bib2], [@bib7]) and shows that astrocytes express Gpc4 in the visual system at the time of synapse initiation.Figure 5Gpc4 Is Expressed by Astrocytes throughout the Developing Visual System(A and B) *In situ* hybridization (ISH) in the developing visual system at P6 shows presence of astrocytes and expression of Gpc4 mRNA. (A) Left: ISH for astrocyte marker Aldh1l1 in the SC at P6. Right: negative control probe, showing absence of signal. (B) ISH for Gpc4 in the visual system at P6 in Gpc4 WT (left) and KO (right)---SC (top), dLGN (middle), and VC (bottom). Gpc4 is expressed in all regions, and there is no signal in the Gpc4 KO. In each set, left, DAPI to mark cell nuclei; middle, low-power image of mRNA probe; and right high-power image of region outlined by red box in low-power image, arrowheads mark positive cells. Note the different image size for VC versus SC and dLGN. Scale bars for (A) and (B), 50 μm.(C--F) Triple fluorescent ISH for Gpc4 and cell-specific markers in the SC (C and D) and VC (E and F) at P6 shows colocalization of Gpc4 with Aldh1l1 and limited overlap with the neuronal marker Tubb3. (C) Gpc4 mRNA (red) colocalizes with Aldh1l1 mRNA (green) and rarely with Tubb3 (blue) in the superficial layers of the SC at P6 in WT (top), absence of Gpc4 signal in Gpc4 KO (bottom). (D) Quantification of (C), fraction of Gpc4+Aldh1l1-positive cells and Gpc4+Tubb3-positive cells. n = 3 mice. (E) Gpc4 (red) mainly colocalizes with Aldh1l1 (green) with limited overlap with Tubb3 (blue) in layer 4 of VC at P6 in WT (top); absence of Gpc4 signal in Gpc4 KO (bottom). In (C) and (E), left panels show merge plus DAPI (inset shows zoom in of boxed region), followed by merge minus DAPI, then single-channel panels as labeled: Gpc4, Aldh1l1, and Tubb3. Arrowheads mark example cells positive for Gpc4 and Aldh1l1. (F) Quantification of (E), fraction of Gpc4+Aldh1l1-positive cells and Gpc4+Tubb3-positive cells. n = 3 mice. Scale bars for (C) and (E), 50 μm, zoomed-in box scale bar, 5 μm. Graphs show mean ± SEM, statistical analysis by t test, p value on graph.See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

Glypican 4 KO Mice Show Increased Retention of NP1 in Presynaptic Terminals *In Vivo* {#sec2.9}
-------------------------------------------------------------------------------------

Given that soluble Gpc4 induces release of NP1 from neurons *in vitro*, we next asked whether the absence of Gpc4 would affect NP1 sub-cellular localization *in vivo*. We predicted that if Gpc4 is necessary to induce release of NP1 from axons, then there would be increased levels of NP1 within presynaptic terminals in Gpc4 KO mice due to a failure of release. To address this question, we performed immunohistochemistry against NP1 in brain sections of the SC from Gpc4 KO and WT littermates at P6, along with VGlut2 to mark RGC presynaptic terminals that form synapses in this region ([Figures 6](#fig6){ref-type="fig"}A--6D; [Figure S5](#mmc1){ref-type="supplementary-material"}A). In Gpc4 KO mice, there was a 1.48-fold ± 0.14-fold increase in NP1 puncta number ([Figure 6](#fig6){ref-type="fig"}C) and increased overlap between NP1 and VGlut2 by 1.51-fold ± 0.03-fold compared to WT ([Figure 6](#fig6){ref-type="fig"}D). This suggests that in the absence of Gpc4, less NP1 is secreted and is instead retained in the presynaptic terminal. There was no difference in the number of VGlut2 puncta (0.92-fold ± 0.05-fold; [Figure 6](#fig6){ref-type="fig"}B), demonstrating that the absence of Gpc4 does not prevent axons from reaching their target or inhibit the formation of presynaptic specializations. The same results were obtained using a second antibody against NP1 ([Figures S5](#mmc1){ref-type="supplementary-material"}C--S5F), and no signal was detected when the primary antibody was omitted ([Figure S5](#mmc1){ref-type="supplementary-material"}G). We then asked whether this effect was specific to RGC projections or present in other parts of the visual system by examining colocalization of NP1 with VGlut2-positive projections from the dLGN to layer 4 of the VC at P6 ([Figures 6](#fig6){ref-type="fig"}E--6H; [Figure S5](#mmc1){ref-type="supplementary-material"}B). As in the SC, in the Gpc4 KO VC, there was a significant increase in NP1 puncta number (1.88-fold ± 0.16-fold; [Figure 6](#fig6){ref-type="fig"}G) and in the number of colocalized NP1-VGlut2 puncta (2.3-fold ± 0.3-fold; [Figure 6](#fig6){ref-type="fig"}H), with no change in VGlut2 (0.95-fold ± 0.06-fold; [Figure 6](#fig6){ref-type="fig"}F).Figure 6Gpc4 KO Mice Have Increased Overlap of NP1 with Presynaptic Terminals in the Developing Visual System *In Vivo*(A--D) Increased colocalization between NP1 and VGlut2 in Gpc4 KO mice in the SC at P6 suggests reduced presynaptic release of NP1 in the absence of Gpc4. (A) Example images from the SC of WT (top) and Gpc4 KO (bottom), VGlut2 in cyan and NP1 in red. (B--D) Quantification of VGlut2, NP1, and colocalized puncta, respectively, normalized to WT.(E--H) Increased colocalization between NP1 and VGlut2 in Gpc4 KO mice in the VC at P6. (E) Example images from the VC of WT (top) and Gpc4 KO (bottom), VGlut2 in cyan and NP1 in red. (F--H) Quantification of VGlut2, NP1, and colocalized puncta, respectively, normalized to WT. In (A) and (E), arrowheads mark representative colocalized puncta. Scale bar, 5 μm.(I) Triple fluorescent ISH for Gpc4- and cell-specific markers in the SC of astrocyte specific Gpc4 KO. Gpc4 (red) colocalizes with Aldh1l1 (green) and rarely with Tubb3 (blue) in the SC at P6 in Gpc4f/y;cre −ve (top), decrease of Gpc4 signal in Gpc4f/y;Aldh1l1cre +ve (bottom). Left panels merge plus DAPI (inset shows zoom in of boxed region), followed by merge minus DAPI, then single-channel panels as labeled: Gpc4, Aldh1l1, and Tubb3. Arrowheads mark example cells positive for Gpc4 and Aldh1l1. Scale bar, 50 μm, zoomed-in box scale bar, 5 μm.(J--M) Increased colocalization between NP1 and VGlut2 in Gpc4f/y;Aldh1l1cre +ve mice in SC at P6, suggests reduced presynaptic release of NP1 in the absence of astrocyte Gpc4. (J) Example images from the SC of Gpc4f/y;cre −ve (top) and Gpc4f/y;cre +ve (bottom), VGlut2 in cyan and NP1 in red. Arrowheads mark representative colocalized puncta. Scale bar, 5 μm. (K--M) Quantification of VGlut2, NP1, and colocalized puncta, respectively, normalized to Gpc4f/y;cre −ve. Graphs show mean ± SEM, number of mice inside the bar. Statistical analysis by t test, p value on graph.See also [Figures S5](#mmc1){ref-type="supplementary-material"} and [S6](#mmc1){ref-type="supplementary-material"}.

To determine whether astrocytes are the major source of Gpc4 responsible for regulating release of NP1 in the visual system at P6, we crossed Gpc4 flox mice to an astrocyte-specific cre line to remove Gpc4 specifically from astrocytes. We screened three different astrocyte-specific cre lines for expression at P3 by crossing them to a tdTomato reporter: GFAPcre77.6, GFAPcre73.12, and Aldh1l1cre ([@bib20], [@bib21], [@bib51]). Only the Aldh1l1cre showed extensive expression of tdTomato in the SC and VC at P3, so we continued experiments with this line ([Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B). As Aldh1l1cre can be expressed in some radial glia and give recombination in late-born neurons ([@bib19], [@bib51]), we immunostained for the neuronal marker NeuN in the Aldh1l1cre;tdTomato brain. This showed little overlap between NeuN and tdTomato in the SC but frequent overlap in the VC ([Figure S6](#mmc1){ref-type="supplementary-material"}C). Based on these regional differences in astrocyte timing and specificity of cre expression, we chose to use Gpc4f/y;Aldh1l1cre mice and analyze the SC at P6. We carried out triple fluorescent ISH for Gpc4, Aldh1l1 (astrocytes), and Tubb3 (neurons). In the Gpc4f/y, we observed overlapping expression of Gpc4 mRNA with Aldh1l1, with little overlap with Tubb3, whereas in the Gpc4f/y;Aldh1l1cre +ve, there was an absence of Gpc4 mRNA in Aldh1l1-positive cells ([Figure 6](#fig6){ref-type="fig"}I). As in the global Gpc4 KO, we carried out immunostaining for VGlut2 and NP1 in the P6 SC and quantified colocalization between them ([Figures 6](#fig6){ref-type="fig"}J--6M). There was a significant increase in NP1 puncta number in the Gpc4f/y;Aldh1l1cre +ve compared to the Gpc4f/y littermates (1.66-fold ± 0.05-fold; [Figure 6](#fig6){ref-type="fig"}L) and an increase in the overlap of NP1 with VGlut2 (1.91-fold ± 0.53-fold; [Figure 6](#fig6){ref-type="fig"}M), with no change in VGlut2 (0.98-fold ± 0.01-fold; [Figure 6](#fig6){ref-type="fig"}K). These results demonstrate that in the absence of astrocyte Gpc4, increased levels of NP1 are present within presynaptic terminals throughout the developing visual system.

RPTPδ KO Mice Show Increased Retention of NP1 in Presynaptic Terminals *In Vivo* {#sec2.10}
--------------------------------------------------------------------------------

Our *in vitro* findings show that Gpc4 signaling through RPTPδ is both necessary and sufficient to induce release of NP1 from RGCs. If RPTPδ is the presynaptic receptor for Gpc4 *in vivo*, then we predict that its removal will phenocopy Gpc4 KO mice, i.e., there will be an increase in the amount of NP1 present within the RPTPδ-lacking presynaptic terminals. To test this, we crossed RPTPδ flox mice to cre lines (see below) to remove RPTPδ from specific subsets of projection neurons in the visual system. In this way, neurons that project axons to form synapses in the target region (presynaptic) have reduced levels of RPTPδ, and neurons in the target zone (i.e., postsynaptic) still expressed RPTPδ, allowing us to differentiate between a pre- and postsynaptic necessity of RPTPδ to synaptic NP1 release. We first examined the *in vivo* localization of RPTPδ mRNA and protein in the developing visual system. RPTPδ mRNA is expressed in the dLGN and VC at P3 and P6 ([Figure 7](#fig7){ref-type="fig"}J, top; [Figures S7](#mmc1){ref-type="supplementary-material"}G and S7H, top). We also examined protein expression of RPTPδ in the retina at P6 using a specific antibody ([Figure S7](#mmc1){ref-type="supplementary-material"}K; [@bib45]) and found that it is present in the retinal ganglion cell layer (GCL) and inner plexiform layer (IPL; [Figure 7](#fig7){ref-type="fig"}A). To determine whether RPTPδ is present in presynaptic terminals of RGC and dLGN neurons *in vivo*, we carried out immunostaining at P6 in the SC and VC, respectively, against VGlut2 and RPTPδ and observed punctate staining for RPTPδ that colocalized with VGlut2 ([Figures 7](#fig7){ref-type="fig"}B and 7K, top). Thus, RPTPδ is present in neurons of the visual system during development and is localized to presynaptic terminals, placing it in the right place at the right time to mediate Gpc4-induced release of NP1.Figure 7RPTPδ cKO Mice Have Increased Overlap of NP1 with Presynaptic Terminals in the Developing Visual System *In Vivo*(A) RPTPδ protein is present in the retina at P6 and is reduced in RPTPδ fl/fl;Pax6-α-cre line (right). RPTPδ immunostaining red, DAPI blue. Arrows mark Ganglion cell layer (GCL) and inner plexiform layer (IPL), showing positive signal for RPTPδ. Scale bar, 20 μm. Boxes show zoomed-in image of GCL neurons; left, RPTPδ and DAPI channels; right, single-channel RPTPδ signal. Scale bar, 5 μm.(B--E) Decreased colocalization between RPTPδ and VGlut2 in RPTPδ f/f;Pax6-α-cre mice in the SC at P6, demonstrating a decrease in the amount of RPTPδ receptor in RGC-SC synapse. (B) Example images from the SC of f/f (top) and f/f;Pax6-α-cre (bottom), VGlut2 in cyan, RPTPδ in red. (C--E) Quantification of VGlut2, RPTPδ, and colocalized puncta, respectively, normalized to f/f.(F--I) Increased colocalization between NP1 and VGlut2 in retina-specific RPTPδ KO mice in SC at P6, suggesting reduced release of NP1 in the absence of presynaptic RPTPδ. (F) Example images from the SC of f/f (top) and f/f;Pax6-α-cre (bottom), VGlut2 in cyan and NP1 in red. (G--I) Quantification of VGlut2, NP1, and colocalized puncta, respectively, normalized to f/f. For (B) and (F), arrowheads mark representative colocalized puncta. Scale bar, 5 μm.(J) RPTPδ mRNA is expressed throughout the developing visual system, and mRNA levels are reduced in the thalamus in RPTPδ f/f;RORα cre line. ISH for RPTPδ mRNA at P3, in f/f (top) and f/f;RORα cre +ve (bottom). Left: low-power images of thalamus and cortex, red box marks VC and red outline marks dLGN, scale bar, 100 μm. Middle is zoom in of dLGN, and right is zoom in of cortex. Scale bar, 100 μm.(K--N) Decreased colocalization between RPTPδ protein and VGlut2 in RPTPδ f/f;RORα-cre +ve VC at P6, demonstrating decreased amount of RPTPδ in dLGN-VC synapse. (K) Example images from the VC of f/f (top) and f/f;RORαcre (bottom), VGlut2 in cyan, RPTPδ in red. (L--N) Quantification of VGlut2, RPTPδ, and colocalized puncta, respectively, normalized to f/f.(O--R) Increased colocalization between NP1 and VGlut2 in thalamus-specific RPTPδ KO mice in the VC at P6. (O) Example images from the VC of f/f (top) and f/f;RORαcre (bottom), VGlut2 in cyan and NP1 in red. (P--R) Quantification of VGlut2, NP1, and colocalized puncta, respectively, normalized to f/f. In (K) and (O), arrowheads mark representative colocalized puncta. Scale bar, 5 μm. Graphs show mean ± SEM, number of mice inside the bar. Statistical analysis by t test, p value on graph.See also [Figure S7](#mmc1){ref-type="supplementary-material"}.

To delete RPTPδ from RGCs, we crossed RPTPδf/f mice to a Pax6-α-cre line ([@bib36]). To visualize the recombination pattern, we crossed the Pax6-α-cre to an EGFP reporter line ([@bib44]) and observed robust GFP expression in multiple layers of the retina, including the GCL, IPL, and a subset of cells in the INL at P6 ([Figure S7](#mmc1){ref-type="supplementary-material"}B). A reduction of RPTPδ in RPTPδ fl/fl;Pax6-α-cre +ve mice was confirmed by a decrease in RPTPδ protein in the retina shown by immunostaining and western blot, compared to cre --ve control ([Figure 7](#fig7){ref-type="fig"}A; [Figure S7](#mmc1){ref-type="supplementary-material"}C). There was also a significant decrease in the overlap of RPTPδ puncta with VGlut2-positive presynaptic terminals in the SC at P6, showing that less receptor is present at the synapse ([Figures 7](#fig7){ref-type="fig"}B--7E). We next examined whether these terminals had increased colocalization between NP1 and VGlut2 (via immunostaining) ([Figures 7](#fig7){ref-type="fig"}F--7I). As in the Gpc4 KO, we observed an increase in NP1 puncta number (1.57-fold ± 0.08-fold; [Figure 7](#fig7){ref-type="fig"}H) and increased colocalization between VGlut2 and NP1 (1.56-fold ± 0.09-fold; [Figure 7](#fig7){ref-type="fig"}I) in the RPTPδ fl/fl;Pax6-α-cre +ve mice compared to cre --ve controls. There was no change in VGlut2 puncta number (0.95-fold ± 0.03-fold; [Figure 7](#fig7){ref-type="fig"}G), demonstrating that removal of RPTPδ did not alter the targeting of axons or the formation of presynaptic terminals.

To further examine the role of RPTPδ in Gpc4-regulated release of NP1, we removed RPTPδ from dLGN axons that project to the VC by crossing RPTPδf/f mice to an RORα cre line ([@bib9]). To visualize the recombination pattern, we crossed RORα cre mice to a tdTomato reporter line ([Figures S7](#mmc1){ref-type="supplementary-material"}D--S7F). Strong expression for tdTomato was observed in the dLGN at P6 ([Figure S7](#mmc1){ref-type="supplementary-material"}D) and in axons in the VC, identified by overlapping staining with the thalamo-cortical presynaptic marker VGlut2 ([Figure S7](#mmc1){ref-type="supplementary-material"}E) and lack of overlap with the intra-cortical presynaptic marker VGlut1 ([Figure S7](#mmc1){ref-type="supplementary-material"}F). Reduction of RPTPδ in RPTPδ fl/fl;RORα cre +ve mice was confirmed by a decrease in RPTPδ mRNA in the thalamus compared to cre --ve controls (shown by ISH), with no alteration in mRNA level in the cortex ([Figure 7](#fig7){ref-type="fig"}J; [Figures S7](#mmc1){ref-type="supplementary-material"}G--S7I). At the protein level, we observed a decrease in RPTPδ in tissue lysates from the thalamus of cre +ve mice compared to --ve by western blot, while the amount of RPTPδ in the hippocampus and VC remained unchanged ([Figure S7](#mmc1){ref-type="supplementary-material"}J). Finally, there was a significant decrease in RPTPδ-VGlut2 colocalization in layer 4 of the VC at P6, showing that less receptor is present at the thalamo-cortical synapse ([Figures 7](#fig7){ref-type="fig"}K--7N). We then examined whether these terminals had increased colocalization between NP1 and VGlut2 (via immunostaining) ([Figures 7](#fig7){ref-type="fig"}O--7R). As above, we observed an increase in NP1 puncta number (1.7-fold ± 0.2-fold; [Figure 7](#fig7){ref-type="fig"}Q), an increase in NP1-VGlut2 colocalization (1.96-fold ± 0.5-fold; [Figure 7](#fig7){ref-type="fig"}R), and no change in VGlut2 puncta number (0.97-fold ± 0.05-fold; [Figure 7](#fig7){ref-type="fig"}P) in the RPTPδ fl/fl;RORα cre +ve mice compared to cre --ve controls. These results demonstrate that when RPTPδ is reduced in the presynaptic terminals, there is an increase in the amount of NP1 present within them, phenocopying the result seen in Gpc4 KO mice.

Gpc4 KO and RPTPδ KO Mice Have Decreased Recruitment of GluA1 to Synapses and Decreased Synapse Number in the Developing Superior Colliculus {#sec2.11}
--------------------------------------------------------------------------------------------------------------------------------------------

Given that mice lacking Gpc4 and RPTPδ show increased presynaptic retention of NP1 *in vivo* ([Figures 6](#fig6){ref-type="fig"} and [7](#fig7){ref-type="fig"}), we next asked whether this pathway is necessary for recruitment of GluA1 to synapses or synapse formation in Gpc4 KO and RPTPδ fl/fl;Pax6-α-cre +ve mice. We carried out immunostaining for VGlut2 and GluA1 in the P6 SC of Gpc4 KO and WT littermates and assayed colocalization of these markers to determine synaptic recruitment of GluA1 ([Figures 8](#fig8){ref-type="fig"}A--8D). We observed a significant decrease in VGlut2-GluA1 colocalization of 0.84-fold ± 0.03-fold ([Figure 8](#fig8){ref-type="fig"}D), with no change in VGlut2 (1.01-fold ± 0.07-fold; [Figure 8](#fig8){ref-type="fig"}B) and a decrease in total GluA1 (0.85-fold ± 0.06-fold; [Figure 8](#fig8){ref-type="fig"}C) in Gpc4 KO mice compared with WT. We then asked whether RPTPδ fl/fl;Pax6-α-cre +ve mice also have decreased synaptic recruitment of GluA1 by immunostaining for the same markers and comparing them to cre --ve littermates ([Figures 8](#fig8){ref-type="fig"}E--8H). There was a significant 0.75-fold ± 0.06-fold decrease in the colocalization of VGlut2 with GluA1 ([Figure 8](#fig8){ref-type="fig"}H), with no change in VGlut2 (1.04-fold ± 0.09-fold; [Figure 8](#fig8){ref-type="fig"}F) and a significant decrease in total GluA1 (0.78-fold ± 0.03-fold; [Figure 8](#fig8){ref-type="fig"}G) in RPTPδ fl/fl;Pax6-α-cre +ve mice. To ask whether structural synapse formation is also affected, we immunostained for VGlut2 and PSD95 in the P6 SC in the same mouse lines, and assayed colocalization of VGlut2 and PSD95 ([Figures 8](#fig8){ref-type="fig"}I--8P). In both the Gpc4 KO and RPTPδ fl/fl;Pax6-α-cre +ve mice, there was a significant decrease in the colocalization of PSD95 with VGlut2, compared to matched controls, of 0.67-fold ± 0.04-fold for Gpc4 KO ([Figure 8](#fig8){ref-type="fig"}L) and 0.83-fold ± 0.04-fold for RPTPδ fl/fl;Pax6-α-cre +ve ([Figure 8](#fig8){ref-type="fig"}P). There was no change in VGlut2 (0.96-fold ± 0.04-fold in Gpc4KO; 1.01-fold ± 0.03-fold in RPTPδ fl/fl;Pax6-α-cre +ve; [Figures 8](#fig8){ref-type="fig"}J and 8N) and a significant decrease in total PSD95 of 0.72-fold ± 0.03-fold in the Gpc4 KO ([Figure 8](#fig8){ref-type="fig"}K) and 0.75-fold ± 0.02-fold in the RPTPδ fl/fl;Pax6-α-cre +ve ([Figure 8](#fig8){ref-type="fig"}O). Taken together, these results demonstrate that astrocyte-secreted Gpc4 acting through presynaptic RPTPδ regulates secretion of NP1 from presynaptic terminals and controls synaptic recruitment of GluA1 and synapse formation in the developing SC.Figure 8Gpc4 KO and RPTPδ cKO Mice Show Decreased Colocalization of GluA1 and PSD95 with VGlut2-Positive Presynaptic Terminals in the Developing Superior Colliculus(A--D) Decreased colocalization between clusters of GluA1 and VGlut2 in Gpc4 KO mice in the SC at P6 shows reduced recruitment of GluA1 to the synapse in the absence of Gpc4. (A) Example images from the SC of WT (top) and Gpc4 KO (bottom), VGlut2 in cyan and GluA1 in red. (B--D) Quantification of VGlut2, GluA1, and colocalized puncta, respectively, normalized to WT.(E--H) Decreased colocalization between clusters of GluA1 and VGlut2 in retina-specific RPTPδ KO (RPTPδ f/f;Pax6-α-cre) mice in the SC at P6 shows reduced recruitment of GluA1 to the synapse in the absence of presynaptic RPTPδ. (E) Example images from the SC of f/f (top) and f/f;Pax6-α-cre (bottom), VGlut2 in cyan and GluA1 in red. (F--H) Quantification of VGlut2, GluA1, and colocalized puncta, respectively, normalized to f/f.(I--L) Decreased colocalization between PSD95 and VGlut2 in Gpc4 KO mice in the SC at P6 shows reduced formation of structural synapses in the absence of Gpc4. (I) Example images from the SC of WT (top) and Gpc4 KO (bottom), VGlut2 in cyan and PSD95 in red. (J--L) Quantification of VGlut2, PSD95, and colocalized puncta, respectively, normalized to WT.(M--P) Decreased colocalization between PSD95 and VGlut2 in retina-specific RPTPδ KO (RPTPδ f/f;Pax6-α-cre) mice in the SC at P6 shows reduced formation of structural synapses in the absence of presynaptic RPTPδ. (M) Example images from the SC of f/f (top) and f/f;Pax6-α-cre (bottom), VGlut2 in cyan and PSD95 in red. (N--P) Quantification of VGlut2, PSD95, and colocalized puncta, respectively, normalized to f/f. Arrowheads mark representative colocalized puncta. Scale bars, 5 μm. Graphs show mean ± SEM, number of mice inside the bar. Statistical analysis by t test, p value on graph.

Discussion {#sec3}
==========

How do neurons know when and where to initiate synapse formation? Previous work showed a correlation between the timing of synaptogenesis and the appearance of astrocytes in the developing brain ([@bib54]). We now identify a molecular mechanism for how this occurs: astrocytes signal to presynaptic axon terminals to increase the release of the AMPAR clustering factor NP1, which interacts with AMPARs on nearby dendrites and initiates nascent synapse formation ([Figure S8](#mmc1){ref-type="supplementary-material"}). We demonstrate that: (1) Gpc4 signals through RPTPs in the presynaptic terminal; (2) Gpc4 upregulates release of the AMPAR-clustering factor NP1 from neurons; (3) binding of NP1 to postsynaptic GluA1 is necessary for Gpc4 to induce AMPAR clustering and synapse formation; and (4) mice lacking either Gpc4 or RPTPδ show increased retention of NP1 in presynaptic terminals, decreased synaptic GluA1, and decreased synapse number *in vivo*.

Astrocytes regulate AMPAR clustering and synapse formation in an indirect fashion by signaling through presynaptic receptors. One advantage of this pathway is that AMPARs will only be clustered once the axon and the target dendrite are both mature enough to undergo synaptogenesis. In this way, astrocytes provide spatial and temporal cues to regulate synapse formation by determining when and where axons release NP1. Neuronal pentraxins are clearly important for clustering AMPARs in development and plasticity ([@bib46]), but the factors regulating NP1 release had not been previously characterized. Here we show that astrocytes, via the release of Gpc4, induce the release of NP1 from presynaptic terminals. Importantly, this effect is specific to the Gpc4 pathway, as the astrocyte-secreted protein TSP1, which induces formation of AMPAR-lacking silent synapses, does not affect NP1 release, highlighting the complexity of the role astrocytes play in synaptogenesis. In future experiments, it will be interesting to determine whether neuronal expressed Gpc4, present in the presynaptic terminals of subsets of neurons, is also able to regulate release of NP1.

Presynaptic RPTPs have been shown to regulate synaptogenesis via *trans*-synaptic binding to postsynaptic receptors, including Slitrks, NGL-3, TrkC, and Il1RAcP; however, little is known about the cellular pathways downstream of receptor-effector interaction ([@bib13], [@bib49]). Interestingly, in some cases, the RPTP GAG-binding sites overlap with those used for *trans*-synaptic interactions ([@bib13], [@bib60]). Heparan sulfate and heparin oligomers compete with TrkC for RPTPσ binding *in vitro* and disrupt TrkC-dependent synaptic differentiation in neuronal co-culture assays ([@bib13]). Binding of Gpc4, an HSPG, to RPTPσ and RPTPδ may also trigger remodeling of such *trans*-synaptic complexes, which likely impacts downstream signaling through RPTPs. We now identify that interaction of soluble Gpc4 with RPTPδ regulates a pathway in the presynaptic terminal that leads to the release of NP1. How interaction between Gpc4 and RPTPδ induces the release of NP1 is still an open question. RPTPs are known to interact with syd-2/liprin-α via their intracellular D2 domain, which affects presynaptic differentiation, so one possibility is that this also regulates NP1 release ([@bib27], [@bib61]). We found that both RPTPδ and RPTPσ are necessary for Gpc4 to induce synaptogenesis, but only RPTPδ was specific to the Gpc4 pathway, as RPTPσ also regulated TSP1-induced synapse formation. One interesting hypothesis is that these two receptors are working together to regulate synaptogenesis. RPTPδ has been reported to regulate the function of RPTPσ via interactions between their D2 domains, so one explanation is that Gpc4 interacting with RPTPδ is upstream of effects through RPTPσ ([@bib55]). Moreover, it has been shown that knocking out both RPTPσ and RPTPδ leads to early lethality, while knockout of individual receptors does not, suggesting that together these receptors are essential for neuronal development ([@bib53]).

What are the functional implications of understanding how astrocyte-secreted Gpc4 induces excitatory synapse formation? A strong correlation has been found between alterations in genes that encode synaptic proteins and neurological disorders, suggesting synaptic dysfunction as an underlying mechanism in disorders such as ASD ([@bib41]). Alterations in astrocyte function have also been shown in a number of neurodevelopmental disorders, including ASD and schizophrenia ([@bib1]). Moreover, alterations in glypicans ([@bib8], [@bib15], [@bib35], [@bib42], [@bib43]) and RPTPδ ([@bib10], [@bib17], [@bib42]) have been linked to the pathophysiology of disorders, including ASD, schizophrenia, ADHD, and neuroticism, and more recently, neuronal pentraxins have been linked to cognitive dysfunction in Alzheimer's disease ([@bib57]). A recent study identified genomic regions known as human accelerated regions (HARs) that are hypothesized to contribute to human evolution and cognition. Interestingly, regions within both Gpc4 and RPTPδ have been identified as potential HARs ([@bib15]), and two cases of ASD with intellectual disability (ID) were found that have point mutations in HARs of Gpc4 causing a significant decrease in Gpc4 expression ([@bib15]). These results strongly suggest that the levels of Gpc4 expressed in the human brain are crucial for brain development and synaptogenesis, with too little Gpc4 leading to ASD and ID. To conclude, we have identified the molecular pathway that astrocyte-secreted Gpc4 acts through to regulate excitatory synaptogenesis, providing novel targets to manipulate to alter synaptic function in health and disease.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Rat anti-HA tagRocheCAT\# 11867423001; RRID: [AB_390918](nif-antibody:AB_390918){#intref0010}Rabbit anti-HA tagSigmaCAT\# H6908; RRID: [AB_260070](nif-antibody:AB_260070){#intref0015}Rabbit anti-FLAGSigmaCAT\# F7425; RRID: [AB_439687](nif-antibody:AB_439687){#intref0020}Rabbit polyclonal anti-Glypican 4ProteintechCAT\# 13048-1-AP; RRID: [AB_10640157](nif-antibody:AB_10640157){#intref0025}Rat monoclonal anti-HomerSerotecCAT\# AHP736; RRID: [AB_324009](nif-antibody:AB_324009){#intref0030}Rabbit polyclonal anti-HomerSanta CruzCAT\# sc-20807; RRID: [AB_2120997](nif-antibody:AB_2120997){#intref0035}Mouse monoclonal anti-PSD95Thermo Fisher ScientificCAT\# MA1-045; RRID: [AB_325399](nif-antibody:AB_325399){#intref0040}Rabbit polyclonal anti-PSD95Life TechnologiesCAT\# 51-6900; RRID: [AB_2533914](nif-antibody:AB_2533914){#intref0045}Mouse monoclonal anti-BassoonEnzoCAT\# VAM-PS003; RRID: [AB_2066982](nif-antibody:AB_2066982){#intref0050}Rabbit polyclonal anti-BassoonSynaptic SystemsCAT\# 141 002; RRID :[AB_887698](nif-antibody:AB_887698){#intref0055}Guinea pig polyclonal anti-VGlut1MilliporeCAT\# AB5905; RRID: [AB_2301751](nif-antibody:AB_2301751){#intref0060}Guinea pig polyclonal anti-VGlut2MilliporeCAT\# AB2251; RRID: [AB_2665454](nif-antibody:AB_2665454){#intref0065}Mouse monoclonal anti-β-tubulinThermo Fisher ScientificCAT\# MA5-16308; RRID: [AB_2537819](nif-antibody:AB_2537819){#intref0070}Mouse monoclonal anti-NP1BD Trans. LabCAT\# 610369; RRID: [AB_397754](nif-antibody:AB_397754){#intref0075}Rabbit polyclonal anti-NP1Thermo Fisher ScientificCAT\# PA514136; RRID: [AB_2236166](nif-antibody:AB_2236166){#intref0080}Rat monoclonal anti-RPTPδDr. F. Nakamura[@bib45]Mouse monoclonal anti-GluA1MilliporeCAT\# MAB2263; RRID: [AB_1977459](nif-antibody:AB_1977459){#intref0085}Rabbit polyclonal anti-GluA1MilliporeCAT\# AB1504; RRID: [AB_2113602](nif-antibody:AB_2113602){#intref0090}Mouse monoclonal anti-NeuNMilliporeCAT\# MAB377; RRID: [AB_2298772](nif-antibody:AB_2298772){#intref0095}Chicken polyclonal anti-GFPMilliporeCAT\# 06-896; RRID: [AB_11214044](nif-antibody:AB_11214044){#intref0100}Goat anti-Rat Alexa 488Molecular ProbesCAT\# A11006; RRID: [AB_141373](nif-antibody:AB_141373){#intref0105}Goat anti-Rat Alexa 594Molecular ProbesCAT\# A11007; RRID: [AB_141374](nif-antibody:AB_141374){#intref0110}Goat anti-Rat Alexa 680Molecular ProbesCAT\# A21096; RRID: [AB_141554](nif-antibody:AB_141554){#intref0115}Goat anti-Mouse Alexa 488Molecular ProbesCAT\# A11029; RRID: [AB_138404](nif-antibody:AB_138404){#intref0120}Goat anti-Mouse Alexa 555Molecular ProbesCAT\# A21424; RRID: [AB_141780](nif-antibody:AB_141780){#intref0125}Goat anti-Mouse Alexa 594Molecular ProbesCAT\# A11032; RRID: [AB_141672](nif-antibody:AB_141672){#intref0130}Goat anti-Mouse Alexa 680Molecular ProbesCAT\# A21057; RRID: [AB_141436](nif-antibody:AB_141436){#intref0135}Goat anti-Rabbit Alexa 488Molecular ProbesCAT\# A11034; RRID: [AB_2576217](nif-antibody:AB_2576217){#intref0140}Goat anti-Rabbit Alexa 594Molecular ProbesCAT\# A11037; RRID: [AB_2534095](nif-antibody:AB_2534095){#intref0145}Goat anti-Rabbit Alexa 647Molecular ProbesCAT\# A21245; RRID: [AB_2535813](nif-antibody:AB_2535813){#intref0150}Goat anti-Rabbit Alexa 680Molecular ProbesCAT\# A21109; RRID: [AB_2535758](nif-antibody:AB_2535758){#intref0155}Goat anti-Guinea pig Alexa 488Molecular ProbesCAT\# A11073; RRID: [AB_142018](nif-antibody:AB_142018){#intref0160}Goat anti-Guinea pig Alexa 594Molecular ProbesCAT\# A11076; RRID: [AB_141930](nif-antibody:AB_141930){#intref0165}Goat anti-Guinea pig Alexa 647Molecular ProbesCAT\# A21450; RRID: [AB_141882](nif-antibody:AB_141882){#intref0170}Goat anti-Chicken Alexa 488Molecular ProbesCAT\# A11039; RRID: [AB_142924](nif-antibody:AB_142924){#intref0175}Goat anti-Mouse (Fab specific)-FITCSigmaCAT\# F4018; RRID: [AB_259572](nif-antibody:AB_259572){#intref0180}**Chemicals, Peptides, and Recombinant Proteins**His-tagged glypican 4This study, Allen lab[@bib2]Alexa 488-tagged NP1This study, Aricescu labN/AGluA1-FabThis study, Aricescu labN/AMut-FabThis study, Aricescu labN/ADulbeco's modified phosphate buffered saline (DPBS)HyCloneCAT\# SH30264PapainWorthingtonCAT\# PAP2 3176Trypsin inhibitorWorthingtonCAT\# LS003086IsolectinVectorCAT\# L-1100TrypsinSigmaCAT\# T9935Poly-D-LysineSigmaCAT\# P6407LamininCultrex TrevigenCAT\# 3400-010-01DMEMThermo Fisher ScientificCAT\# 11960044NeurobasalThermo Fisher ScientificCAT\# 21103049Penicillin-StreptomycinThermo Fisher ScientificCAT\# 15140-122GlutamaxThermo Fisher ScientificCAT\# 35050-061Sodium pyruvateThermo Fisher ScientificCAT\# 11360-070FBSThermo Fisher ScientificCAT\# 10437028N-acetyl-L-cysteineSigmaCAT\# A8199InsulinSigmaCAT\# I1882Triiodo-thyronineSigmaCAT\# T6397TransferrinSigmaCAT\# T1147BSASigmaCAT\# A4161ProgesteroneSigmaCAT\# P6149PutrescineSigmaCAT\# P5780Sodium seleniteSigmaCAT\# S9133ForskolinSigmaCAT\# F6886FUDRSigmaCAT\# F0503AraCSigmaCAT\# C1768HydrocortisoneSigmaCAT\# H0888B27/NS21[@bib56]N/ABDNFPeprotechCAT\# 450-02CNTFPeprotechCAT\# 450-13Complete Protease Inhibitor cocktailSigmaCAT\# 04693132001Mouse Thrombospondin 1R&D SystemsCAT\# NP_035710RPTP wedge sigma peptideSalk Peptide CoreN/ARPTP wedge scrambled sigma peptideSalk Peptide CoreN/ARPTP wedge LAR peptideSalk Peptide CoreN/ARPTP wedge delta peptideSalk Peptide CoreN/AReducing sample bufferThermo Fisher ScientificCAT\# 390001% caesinBioradCAT\# 1610782TBSBio-worldCAT\# 105300272Actinomycin DThermo Fisher ScientificCAT\# 11805017Cell tracker red CMPTX dyeThermo Fisher ScientificCAT\# C3455216% PFA solutionEMSCAT\# 50980487PFA powderEMSCAT\# 19208L-lysineSigmaCAT\# L5501Goat serumThermo Fisher ScientificCAT\# 16210072SlowFade Gold with DAPI mounting mediaThermo Fisher ScientificCAT\# S36939Triton X-100SigmaCAT\# T9284DAPIMilliporeCAT\# 5.08741.0001Cytoseal mounting mediaThermo Fisher ScientificCAT\# 8312-4KetamineVictor Medical CompanyN/AXylazineAnasedN/A**Critical Commercial Assays**Lipofectamine 2000Thermo Fisher ScientificCAT\# 11668-019Bradford assayBio-FadCAT\# 5000203QIAGEN maxi kitQIAGENCAT\# 12362QIAGEN RNeasy mini kitQIAGENCAT\# 74104Affymetrix Rat Genome 230 2.0 arraysAffymetrixCAT\# 900505Power Sybr green Cell-to-Ct kitThermo Fisher ScientificCAT\# 4402954RNAscope 2.5 HD---BROWN Manual AssayACDbioCAT\# 322300RNAscope 2.5 HD---multiplex fluorescent Manual AssayACDbioCAT\# 320850**Deposited Data**Affymetrix microarray dataGene Expression OmnibusGEO: [GSE86595](ncbi-geo:GSE86595){#intref0185}**Experimental Models: Cell Lines**HEK293 cell lineATCCCAT\# CRL-1573; RRID: CVCL_0045HEK293T cell lineATCCCAT\# CRL-3216; RRID: CVCL_0063T11D7e2 HybridomaATCCCAT\# TIB-103; RRID: CVCL_F769**Experimental Models: Organisms/Strains**Rats: CD Sprague-DawleyCharles RiversStock \#001; RRID: RGD_10395233**Experimental Models: Mice**C57Bl6/JJackson LaboratoryJax\# 000664; RRID: IMSR_JAX:000664C57BL/6N-Gpc4tm2a(EUCOMM)Wtsi/JJackson LaboratoryJax\# 025147; MGI:[4432991](mgi:4432991){#intref0190}B6.129S4-Gt(ROSA)26Sortm1(FLP1)Dym/RainJJackson LaboratoryJax\# 009086; RRID: IMSR_JAX:009086B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/JJackson LaboratoryJax\# 007914; RRID: IMSR_JAX:007914B6;FVB-Tg(Aldh1l1-cre)JD1884Htz/JJackson LaboratoryJax\# 023748; RRID: IMSR_JAX:023748B6.Cg-Tg(Gfap-cre)77.6Mvs/2JJackson LaboratoryJax\# 024098; RRID: IMSR_JAX:024098B6.Cg-Tg(Gfap-cre)73.12Mvs/JJackson LaboratoryJax\# 012886; RRID: IMSR_JAX:012886Ptprdtm2a(KOMP)WtsiEMMA Mouse RepositoryEM:06697; MGI:[4458607](mgi:4458607){#intref0195}RORα-IRES-CreProf. D. O'Leary([@bib9])Pax6-α-CreProf. D. O'Leary([@bib36])B6;129S5-Gpc4tm1Lex/MmucdMMRRC032331-UCD; RRID: MMRRC_032331-UCD**Oligonucleotides**siRNA targeting rat NP1DharmaconCAT\# LQ-098200-02siControl non-targeting siRNADharmaconCAT\# D-001810-10qPCR primer GAPDH forward TGCCACTCAGAAGACTGTGGIDTN/AqPCR primer GAPDH reverse GCATGTCAGATCCACAATGGIDTN/AqPCR primer NP1 forward\
TGCAAAGATCACTTCGTCACCIDTN/AqPCR primer NP1 reverse\
CCAACACACCTTCAAGATCCAIDTN/AqPCR primer NP2 forward AGCGTCTCCTGGACTTGTAGCIDTN/AqPCR primer NP2 reverse CTTCCCACCAAAGAACAAAGCIDTN/AqPCR primer NPR forward CAACCATCGGCTTGTAGATGAIDTN/AqPCR primer NPR reverse GGAGGAGACCCTTCTCCAGTTIDTN/ARNAscope probe: negative controlACDbioCAT\# 310043RNAscope probe: double negative controlACDbioCAT\# 320751RNAscope probe: triple negative controlACDbioCAT\# 320871RNAscope probe: Aldh1l1ACDbioCAT\# 405891RNAscope probe: Aldh1l1 channel 2ACDbioCAT\# 405891-C2RNAscope probe: Gpc4ACDbioCAT\# 442821RNAscope probe: PTPRDACDbioCAT\# 474651RNAscope probe: Tubb3 channel 3ACDbioCAT\# 423398-C3**Recombinant DNA**Rat full length glypican 4 with an N-terminal 6 Histidine (His)This study, Allen lab[@bib2]Mouse NP1, full lengthThis study, Aricescu labN/AHuman RPTPσ (full length, short isoform, N-terminally HA-tagged)This study, Aricescu labN/AHuman RPTPδ (full length, short isoform, N-terminally HA-tagged)This study, Aricescu labN/AHuman LAR (full length, N-terminally HA-tagged)This study, Aricescu labN/ApEGFP-N1, ClontechAddgeneCAT\# 6085-1Rat RPTPσDharmaconCAT\# MRN1768-202786786Mouse RPTPδ[@bib45]N/AMouse GluA1, GluA2, GluA3 & GluA4 ATDThis study, Aricescu labN/AMouse GluA1, GluA3 & GluA4 full lengthThis study, Aricescu labN/ARat GluA2, full lengthThis study, Aricescu labN/A**Software and Algorithms**ImarisBitplaneRRID: SCR_007370ImageJ (Fiji)NIHRRID: SCR_003070ZenZeissRRID: SCR_013672AxioVisionZeissRRID: SCR_002677SDS 2.4Applied BiosystemsN/AExpression ConsoleAffymetrixN/ASigmaplotSystatRRID: SCR_003210MetamorphMolecular DevicesRRID: SCR_002368Odyssey Image StudioLi-CorRRID: SCR_014211Scrubber 2.0BioLogic Software<http://www.biologic.com.au/>GraphPad PrismPrismRRID: SCR_002798**Other**Glass coverslips, 13mmCarolina Biological Supply CompanyCAT\# 633029Cell culture insertsThermo Fisher ScientificCAT\# 353104Centrifuge columnThermo Fisher ScientificCAT\# 89896Vivaspin centrifugal concentratorSartoriusCAT\# 145585024%--12% bolt gelsThermo Fisher ScientificCAT\# NW04120PVDF membranes, Immobilon-FLMilliporeCAT\# IPFL00005Odyssey Infrared ImagerLi-CorN/AGlass slidesFisherCAT\# 125442Fluorescence microscopeZeissAxio Imager.Z2OCT media, ScigenFisherCAT\# 4583TFM tissue freezing mediaGeneral Data HealthcareCAT\# TFM-5CryostatHacker IndustriesOTF5000Superfrost Plus glass slidesFisherCAT\# 1255015Glass coverslips, 1.5FisherCAT\# 12544EConfocal MicroscopeZeissLSM710Confocal MicroscopeZeissLSM780Confocal MicroscopeZeissLSM880Confocal MicroscopeLeicaTCS SP8HybEZ hybridization systemACDbioN/A

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Nicola J. Allen (<nallen@salk.edu>).

Experimental Models {#sec4.3}
-------------------

### Animals {#sec4.3.1}

All animal work was approved by the Salk Institute Institutional Animal Care and Use Committee (IACUC).

#### Rats {#sec4.3.1.1}

Sprague Dawley rats (Charles Rivers) were maintained in the Salk Institute animal facility, under a 12 hour light:dark cycle with *ad libitum* access to food and water. Rat pups (both male and female) were used at post-natal day (P) 1-2 for preparation of primary cortical astrocyte cultures, and at P5-P7 for preparation of purified immunopanned retinal ganglion cell (RGC) neuronal cultures.

#### Mice {#sec4.3.1.2}

Mice were maintained in the Salk Institute animal facility, under a 12 hour light:dark cycle with *ad libitum* access to food and water. The following mouse lines were used:

#### Gpc4 KO {#sec4.3.1.3}

The mouse strain used for this research project, B6;129S5-Gpc4tm1Lex/Mmucd, identification number 032331-UCD, was obtained from the Mutant Mouse Regional Resource Center, a NCRR-NIH funded strain repository, and was donated to the MMRRC by Genentech, Inc. This is the same mouse line we previously characterized ([@bib2]). Mice were backcrossed to C57Bl6/J background (Jax: 000664) for at least 6 generations prior to conducting experiments. For the generation of experimental mice, mice were bred as Gpc4+/− (het) female x Gpc4+/y (WT) male. All experiments were performed using male WT and KO littermates (Gpc4 is on the X chromosome, so experiments compared Gpc4+/y with Gpc4-/y).

#### Gpc4 Conditional KO {#sec4.3.1.4}

C57BL/6N-Gpc4tm2a(EUCOMM)Wtsi/J were obtained from Jackson Labs (025147). To generate the tm2c mice with a floxed Gpc4 allele, tm2a mice were crossed to the Rosa Flp1 line (Jax: 009086) to remove the neomycin cassette. This produces a line where exon 3 (ENSMUSE00000310079) of Gpc4 (ENSMUST00000033450.2) is floxed. Upon exposure to cre recombinase this will remove exon 3 leading to a frameshift and premature stop codon, which is predicted to lead to nonsense mediated decay of the mRNA. Characterization of this line is shown in [Figure 6](#fig6){ref-type="fig"}. Mice were maintained as homozygous for floxed Gpc4 on a C57Bl6/J background, and crossed to mice expressing cre recombinase (see below) for experiments.

#### RPTPδ Conditional KO {#sec4.3.1.5}

We thank the Wellcome Trust Sanger Institute Mouse Genetics Project (Sanger MGP) and its funders for providing the mutant mouse line (Ptprdtm2a(KOMP)Wtsi). Funding and associated primary phenotypic information may be found at <http://www.sanger.ac.uk/science/collaboration/mouse-resource-portal>. To generate the tm2c mice with a floxed RPTPδ allele, tm2a mice were crossed to the Rosa Flp1 line (Jax: 009086) to remove the neomycin cassette. This produces a line where exon 22 (ENSMUSE00000526394) of the consensus sequence (ENSMUST00000173376.7) is floxed, which is within the D1 phosphatase domain of RPTPδ ([Figure S7](#mmc1){ref-type="supplementary-material"}A). Upon exposure to cre recombinase this will remove exon 22 leading to a frameshift and premature stop codon, which is predicted to lead to nonsense mediated decay of the mRNA. Characterization of this line is shown in [Figures 7](#fig7){ref-type="fig"} and [S7](#mmc1){ref-type="supplementary-material"}. This is a similar targeting strategy as used to generate mice with a null allele of RPTPδ, where exon 20 was targeted at the start of the phosphatase domain ([@bib52]). Mice were maintained as homozygous for floxed RPTPδ on a C57Bl6/J background, and crossed to mice expressing cre recombinase for experiments.

#### RORα-IRES-Cre {#sec4.3.1.6}

*RORα-IRES-Cre* mice were obtained from Dennis O'Leary at the Salk Institute, and described in [@bib9]. Mice were backcrossed to C57Bl6/J (Jax:000664) for 3-4 generations before being crossed to the RPTPδ flox line. Expression of cre recombinase in the thalamus was confirmed by crossing the RORα cre mouse with a tdTomato reporter mouse line (Jax: 007914) ([Figures S7](#mmc1){ref-type="supplementary-material"}D--S7F). For the generation of experimental mice, mice were bred as RPTPδ^f/f^;cre-ve x RPTPδ^f/f^;RORα cre+ve. Homozygous flox RPTPδ mice positive or negative for RORα cre were compared in each experiment; both male and female mice were used.

#### Pax6-α-Cre {#sec4.3.1.7}

*Pax6-α-Cre* mice were generated by Peter Gruss lab at the Max Planck Institute of Biophysical Chemistry, Gottigen, Germany as described in [@bib36] and obtained from Dennis O'Leary lab at the Salk Institute. Mice were backcrossed to C57Bl6/J (Jax:000664) for 3-4 generations before being crossed to the RPTPδ line. Expression of cre recombinase in the retina was confirmed by crossing Pax6-α-cre mice with a GFP reporter mouse line ([Figures S7](#mmc1){ref-type="supplementary-material"}B and S7C). For the generation of experimental mice, mice were bred as RPTPδ^f/f^;cre-ve x RPTPδ^f/f^;Pax6-α-cre+ve. Homozygous flox RPTPδ mice positive or negative for Pax6-α-cre were compared in each experiment; both male and female mice were used.

#### GFAP-Cre 77.6 {#sec4.3.1.8}

*GFAP-Cre 77.6* mice were obtained from Jackson Labs (024098). Expression of cre recombinase in astrocytes was determined by crossing the cre mouse with a tdTomato reporter mouse line (Jax: 007914) ([Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B).

#### GFAP-Cre 73.12 {#sec4.3.1.9}

*GFAP-Cre 73.12* mice were obtained from Jackson Labs (012886). Expression of cre recombinase in astrocytes was determined by crossing the cre mouse with a tdTomato reporter mouse line (Jax: 007914) ([Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B).

#### Aldh1l1-Cre {#sec4.3.1.10}

*Aldh1l1-Cre* mice were obtained from Jackson Labs (023748). Expression of cre recombinase in astrocytes was determined by crossing the cre mouse with a tdTomato reporter mouse line (Jax: 007914) ([Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B). For the generation of experimental mice, mice were bred as Gpc4^f/f^ cre-ve female x Aldh1l1cre+ve male. Hemizygous flox Gpc4 male mice (Gpc4^f/y^) positive or negative for Aldh1l1 cre were compared in each experiment.

#### Tissue Collection {#sec4.3.1.11}

Mice were collected at P6-7 unless stated otherwise in the text. For each experiment WT and KO littermates were collected and analyzed at the same time for comparison.

### Cell Culture {#sec4.3.2}

#### Retinal Ganglion Cell (RGC) Neuron Purification and Culture {#sec4.3.2.1}

RGC purification and culture was performed as described ([@bib2], [@bib54], [@bib56]). Briefly, retinas from P5-P7 rat pups of both sexes were removed and placed in DPBS (HyClone Cat. SH30264). Retinas were digested with Papain (Worthington Cat. PAP2 3176; 50 units) for 30 min at 34C, triturated with Low OVO (15 mg/ml trypsin inhibitor (Worthington Cat. LS003086)), then High OVO (30 mg/ml trypsin inhibitor (Worthington cat. LS003086)) solutions. The cell suspension was then added to lectin (Vector Cat. L-1100) coated Petri dishes to pull down microglia and fibroblast cells for 5-10 min at room temp. The remaining cells were then added to T11D7 hybridoma supernatant coated Petri dishes for 40 min at room temp, which specifically binds RGCs. After washing off the non-binding cells with DPBS, pure RGCs were released by trypsin treatment (Sigma Cat. T9935) to cleave cell-antibody bond, and collected. RGCs were plated on glass coverslips (Carolina Biological Supply Company Cat. 633029) coated with PDL (Sigma Cat. P6407) and laminin (Cultrex Trevigen Cat. 3400-010-01) at a density of 20,000-30,000 cells/well in a 24 well plate or 10,000 cells/well in 48 well plates. RGCs were maintained in the following media: 50% DMEM (Life tech Cat. 11960044); 50% Neurobasal (Life Tech Cat. 21103049); Penicillin-Streptomycin (LifeTech Cat. 15140-122); glutamax (Life Tech Cat. 35050-061); sodium pyruvate (Life Tech Cat. 11360-070); N-acetyl-L-cysteine (Sigma Cat. A8199); insulin (Sigma Cat. I1882); triiodo-thyronine (Sigma Cat. T6397); SATO (containing: transferrin (Sigma T-1147); BSA (Sigma A-4161); progesterone (Sigma P6149); putrescine (Sigma P5780); sodium selenite (Sigma S9133)); and B27 (see [@bib56] for recipe). For complete growth media, the media was supplemented with BDNF (Peprotech Cat. 450-02), CNTF (Peprotech Cat. 450-13), and forskolin (Sigma Cat. F6886). The next day, half of the media was replaced with media containing FUDR (13 μg/μl final concentration Sigma Cat. F0503) to inhibit fibroblast growth. Cells were fed by replacing half of the media with fresh equilibrated media every 3-4 days. RGCs were maintained at 37C/10%CO2 and kept in culture for at least 7 days prior to treatment to allow for full process outgrowth.

#### Astrocyte Preparation and Culture {#sec4.3.2.2}

Primary astrocytes from rat cortex were prepared as described ([@bib2], [@bib37]). Briefly, the cerebral cortex from P1-P2 rat pups were removed and placed in DPBS (HyClone Cat. SH30264). The meninges and hippocampi were removed and discarded. The remaining cortices were diced and digested with Papain (Worthington Cat. LS003126; 330 units) for 1 hr and 15 min in 37C 10% CO2 cell culture incubator. Cells were triturated in Low OVO and then High OVO containing solutions, and plated in PDL coated 75cm tissue culture flasks. 3 days after plating, flasks were manually shaken to remove upper cell layers which contained mostly non astrocytic cells. 2 days after shake off, ARA-C (10 μM final concentration; Sigma Cat. C1768) was added for 48 hours to inhibit the other proliferating cells, which divide faster than astrocytes. Finally, astrocytes were plated in 15 cm cell culture plates coated with PDL at 2-3 million cells/dish and passaged once a week. Astrocytes were maintained at 37C/10%CO2 and kept in culture for 3-4 weeks. Astrocyte culture medium was DMEM (Life tech Cat. 11960044) supplemented with 10% Heat inactivated FBS (LifeTech Cat. 10437028), Penicillin-Streptomycin (LifeTech Cat. 15140-122), glutamax (Life Tech Cat. 35050-061), sodium pyruvate (Life Tech Cat. 11360-070), hydrocortisone (Sigma Cat. H0888), and N-acetyl-L-cysteine (Sigma Cat. A8199). Depending on the specific requirement of the experiments, astrocytes were either plated on cell culture inserts (Falcon Cat. 353104) at 50,000 cell/ insert or kept in 15 cm dishes and used to prepare astrocyte conditioned media (ACM).

#### HEK293 Cells {#sec4.3.2.3}

HEK293 cells (ATCC Cat. CRL-1573, without the T antigen) were obtained from the Evans lab at the Salk Institute. Cell lines were maintained at 37C/5%CO2 in the following media: DMEM (Life tech Cat. 11960044) supplemented with 10% Heat inactivated FBS (LifeTech Cat. 10437028), 1% Penicillin-Streptomycin (LifeTech Cat. 15140-122), 1% glutamax (Life Tech Cat. 35050-061) and 1% sodium pyruvate (LifeTech Cat. 11360-070), and passaged once a week.

#### HEK293T Cells {#sec4.3.2.4}

HEK293T cells (ATCC Cat CRL-3216) were cultured in DMEM (GIBCO Cat. 31966-021) supplemented with 10% Fetal Bovine Serum (FBS) (GIBCO Cat. No. 10270-106), 1x MEM Non-Essential Amino Acids (GIBCO Cat. 11140-035) and 2mM L-Glutamine (GIBCO Cat. 25030-024).

Method Details {#sec4.4}
--------------

### cDNA Constructs {#sec4.4.1}

The following cDNA constructs were used, and transfected into cells using lipofectamine 2000 (Life Tech Cat. 11668-019) unless stated otherwise in the text, according to the manufacturer's instructions.

*GFP:* pEGFP-N1 mammalian expression vector (Clontech, Addgene cat. 6085-1)

*Glypican 4:* Rat full length glypican 4 with an N-terminal 6 Histidine (His) tag sub-cloned into pAPtag5 vector (GenHunter) between the SfiI and XhoI sites ([@bib2]).

The full-length RPTP constructs were sub-cloned into the pHLsec vector between AgeI and KpnI restriction sites ([@bib3]), downstream of the secretion signal sequence provided by the vector and a sequence encoding the HA-tag (YPYDVPDYA).

*Human RPTPσ* (full length, short isoform, N-terminally HA-tagged; UniProt ID: Q13332-7, residues: 30-1501);

*Human RPTPδ:* (full length, short isoform, N-terminally HA-tagged; UniProt ID: [Q3KPI9](uniprotkb:Q3KPI9){#intref0215}, residues: 21-1496);

*Human LAR:* (full length, N-terminally HA-tagged; UniProt ID: [P10586](uniprotkb:P10586){#intref0220}, residues: 30-1907).

*Mouse RPTPδ:* construct used to validate the specificity of the RPTPδ antibody ([Figure S7](#mmc1){ref-type="supplementary-material"}K) was as described in [@bib45].

*Rat RPTPσ:* Dharmacon (Cat. MRN1768-202786786)

*Mouse neuronal pentraxin 1:* (NP1, UniProt ID: [Q62443](uniprotkb:Q62443){#intref0225}, residues: 23-432) was synthesized and codon optimized for expression in human cells, and cloned into the pHL-Avitag3 vector ([@bib3]) between AgeI and KpnI sites.

### Recombinant Proteins {#sec4.4.2}

#### His-Tagged Glypican 4 {#sec4.4.2.1}

His-tagged glypican 4 was purified as described ([@bib2]). Briefly, HEK293 cells were transfected with His-glypican 4 cDNA using lipofectamine 2000 (Life Tech Cat. 11668-019), according to the manufacturer's instructions. Cells were then placed in conditioning media (see ACM preparation) and incubated for 3 days. The secreted glypican 4 was purified by incubating conditioning media with Ni-coated agarose beads over night at 4C. The next day the beads were washed 5 times with cold DPBS supplemented with protease inhibitors cocktail (Roche Cat. 04693132001) to remove nonspecific binding and loaded onto a centrifuge column (Thermo Cat. 89896). Glypican 4 was eluted from the beads by washing the column with DPBS with 250 mM imidazole (high concentration of imidazole disrupts the bond between Histidine and Nickel). Finally, 2 media substitution steps were performed using concentrators (Sartorius Cat. 14558502) to achieve purified glypican 4 diluted in sterile DPBS. Amount and quality of protein were assessed by western blot (data not shown), and the amount of glypican 4 to treat RGCs was matched to the amount measured in 25 μg of ACM, as described in [@bib2]. Purified glypican 4 was kept at 4C and used within 3-4 weeks.

#### Recombinant Mouse Thrombospondin1 (TSP1) {#sec4.4.2.2}

Recombinant mouse Thrombospondin1 (TSP1) was purchased from RandD (Cat. NP_035710); aliquoted, snap frozen and stored at −80C. The amount of TSP1 added to cells was experimentally determined by adding different doses to RGCs and performing immunostaining for synaptic markers. The amount which induced the most robust synapse formation was chosen for subsequent experiments and was 0.25 μg/ml.

#### RPTP Wedge Domain-Blocking Peptides {#sec4.4.2.3}

RPTP wedge domain-blocking peptides ([@bib33]) were synthesized in the Salk Peptide Synthesis Core using standard Fmoc chemistry, and subsequently HPLC-purified to \> 95% and converted to the acetate salt at 21st Century Biochemicals, Inc. The lyophilized peptides were rehydrated in sterile double distilled water, aliquoted and snap frozen. Aliquots were kept at −80C until use. 2.5 μM final concentrations were used from each peptide. Each peptide has a TAT sequence (GRKKRRQRRR) which makes it cell permeant.

The following sequences of peptides were used:

Sigma: GRKKRRQRRRCDMAEHMERLKANDSLKLSQEYESI-amide

Scrambled Sigma: GRKKRRQRRRCIREDDSLMLYALAQEKKESNMHES-amide

LAR: GRKKRRQRRRCDLADNIERLKANDGLKFSQEYESI-amide

Delta: GRKKRRQRRRCELADHIERLKANDNLKFSQEYESI-amide

#### Alexa488-Tagged NP1 {#sec4.4.2.4}

Full length mouse neuronal pentraxin 1 (NP1, UniProt ID: [Q62443](uniprotkb:Q62443){#intref0230}, residues: 23-432) was synthesized and codon optimized for expression in human cells. The construct was cloned into the pHL-Avitag3 vector ([@bib3]) between AgeI and KpnI sites and transfected into HEK293T cells using 1mg/ml Polyethylenimine (PEI) (Sigma Cat. 408727) as described ([@bib3]). Conditioned medium was harvested two days after transfection, centrifuged at 5000xg for 30 minutes and sterile filtered (0.22 μm Stericup, Millipore Cat. SCGPU05RE/Steri). The protein was affinity-purified using Talon beads (Clontech Cat. 635503) followed by size exclusion chromatography on a Superose 6 Increase 3.2/300 column (GE Healthcare Cat. 29-0915-98). Peak fractions were pooled together and concentrated to 1 mg/ml. 100 μL pure protein was labeled with Alexa Fluor 488 using a kit from Invitrogen (Cat. A20181). Labeled protein was protected from light, aliquoted and flash-frozen in liquid nitrogen until use.

### GluA1-Fab Generation {#sec4.4.3}

#### Hybridoma Generation {#sec4.4.3.1}

Custom peptide antigens corresponding to helix α9 and the loop leading up to helix α10 of the amino-terminal domain (ATD) of mouse AMPA-type glutamate receptor subunit 1 (GluA1; *C*DTIPARIMQQWRTSDARDHTRVDWKR, 27aa; UniProt ID: [P23818](uniprotkb:P23818){#intref0235}; residues 242-267) were synthesized and conjugated to the immunogenic keyhole limpet hemocyanin (KLH) via an N-terminal cysteine. Five BALB/c mice were intraperitoneally injected with 50 μg immunogen emulsified with Freund's Complete Adjuvant. Two weeks later, mice received a first boost of 25 μg immunogen in Freund's Incomplete Adjuvant. Two subsequent boosters were given at three week intervals. Test bleeds were collected a day before initial immunization and seven days after each booster injection. Serum samples were screened against recombinant mouse heteromeric GluA1/GluA2 AMPA receptors expressed on the surface of live HEK293T cells ([@bib32]). The host animal with positive serum antibodies was used as a splenic B cell donor to produce a hybridoma for mouse monoclonal anti-GluA1 antibodies.

#### Anti-GluA1 Fab Fragment Generation {#sec4.4.3.2}

Total RNA was isolated from cultured GluA1 hybridoma generated above, and first-strand cDNA synthesized from the purified RNA by RT-PCR with random hexamers (SuperScript™ III First-Strand Synthesis System, Thermo Fisher Cat. 18080051). cDNA constructs coding for the γ heavy chain, fused C-terminally with a hexa-histidine (His6) tag, and the κ light chain of mouse IgG antibody Fab fragments were amplified by PCR (Pyrobest Polymerase, Takara Bio Cat. R005A) using a set of degenerate primers ([@bib28]). The resulting PCR products were cloned into the pHLsec vector ([@bib3]).

#### GluA1-Fab Fragment γ Heavy Chain {#sec4.4.3.3}

The following degenerate primer pair was used for the PCR amplification of mouse anti-GluA1 Fab fragment γ heavy chain (degenerate bases underlined and variations indicated beneath):

FP: 5′-CGCACCGGTCAG[C]{.ul}TG[CA]{.ul}GCA[G]{.ul}TCTGGA-3′

T GT A

RP: 5′-ATACTCGAGTCATTAATGGTGGTGATGGTGATGAGTACCGCAGTC TCTGGGGACGATCTTCTTGTCGACCTTGGTGCTGCTGGCCGGGTG-3′

#### GluA1-Fab Fragment κ Light Chain {#sec4.4.3.4}

The following degenerate primer pair was used for the PCR amplification of mouse anti-GluA1 Fab fragment κ light chain (degenerate bases underlined and variations indicated beneath):

FP: 5′-CGCACCGGTGAT[GT]{.ul}T[G]{.ul}TGATGACCCAAACTCCA-3′

AC T

RP: 5′-ATACTCGAGTCATTAACACTCATTCCTGTTGAAGC-3′

#### Mut-Fab Fagment {#sec4.4.3.5}

A control protein was engineered by introducing a mutation to the complementarity-determining region (CDR) of the Fab fragment. Three residues on the hypervariable H3 loop of the γ heavy chain were replaced with an elongated sequence (CGR[WDD]{.ul}MDY to CGR[NWEGWY]{.ul}MDY). cDNA coding for the mutant γ heavy chain was cloned into the pHLsec vector ([@bib3]).

#### Production and Purification of Fab Fragments {#sec4.4.3.6}

For large-scale protein production, proteins were expressed by transient transfection in HEK293T cells in a 1:1 heavy chain:light chain stoichiometric ratio. Five days post-transfection, the conditioned medium was collected and buffer-exchanged using a QuixStand benchtop diafiltration system (GE Healthcare, Cat. 56-4107-78) and proteins were purified by immobilized metal-affinity chromatography (IMAC) using pre-packed Ni-Sepharose columns (HisTrap™ HP, GE Healthcare, Cat. 17-5248-02). Proteins were concentrated and further purified by size-exclusion chromatography (SEC; Superdex^®^ 200 16/60 PG HiLoad column, GE Healthcare, Cat. 28989335) in Dulbecco's phosphate-buffered saline (DPBS) with Ca^2+^ and Mg^2+^ (Sigma-Aldrich, Cat. D8662).

### GluA1-Fab Fragment Specificity Analysis {#sec4.4.4}

#### Surface Plasmon Resonance (SPR) {#sec4.4.4.1}

cDNA constructs coding for the amino-terminal domains of mouse GluA1 (UniProt ID: [P23818](uniprotkb:P23818){#intref0240}, residues: 19-393), GluA2 (UniProt ID: [P23819](uniprotkb:P23819){#intref0245}, residues: 22-400), GluA3 (UniProt ID: [Q9Z2W9](uniprotkb:Q9Z2W9){#intref0250}, residues: 24-404) and GluA4 (UniProt ID: [Q9Z2W8](uniprotkb:Q9Z2W8){#intref0255}, residues 21-401) were cloned into the pHLsec-Avitag3 vector ([@bib3]) between the AgeI and KpnI sites, resulting in proteins carrying C-terminal biotin ligase (Avitag) ([@bib25]) and hexa-His tags. Constructs were co-transfected with pDisplay-BirA-ER (Addgene plasmid 20856) to express an ER-resident biotin ligase for *in vivo* biotinylation in HEK293T cells in small-scale 6-well plates in a 3:1 pHLsec:pDisplay stoichiometric ratio. A concentration of 100 μM D-biotin was maintained in the expression medium to ensure near-complete biotinylation of the recognition sequence. After 48 hours of expression, conditioned medium was collected and dialyzed against 10mM Tris pH 7.4, 150mM sodium chloride, 2mM calcium chloride, 2mM magnesium chloride and 0.005% (v/v) Tween-20.

SPR experiments were performed on a Biacore™ T200 machine (GE Healthcare) operated at a data collection frequency of 10 Hz; i.e., a temporal resolution of 0.1 s. Streptavidin (Sigma-Aldrich Cat. S4762) was chemically coupled via amine coupling chemistry onto CM5 chips to a response unit (RU) level of 2000 RU. Then, the biotinylated ATD constructs were captured to a level of 500 RU. The immobilized ligand sensor surface was equilibrated in SPR running buffer supplemented with 1.0g/L bovine serum albumin (BSA) to attain a stable baseline. 14 concentrations of GluA1-Fab and Mut-Fab were prepared in a two-fold dilution series from a 10 μM stock concentration. Injections were performed in order of ascending concentration, followed by descending concentration, i.e., each concentration was sampled in duplicate within the same experiment. Each analyte sample was injected for 180 s at a flow rate of 10 μl/min, followed by a 200 s dissociation phase. The surfaces were regenerated using a 600 s injection of 50mM L-Arginine/L-Glutamate at 20 μl/min. For every two analyte binding cycles, a buffer injection was performed, allowing for double referencing of the binding responses ([@bib39]). No regeneration was performed after buffer injections. Equilibrium binding analysis was performed using Scrubber 2.0 (BioLogic Software, <http://www.biologic.com.au/>) and data was fitted to a 1:1 Langmuir binding model in Prism 6 (Graphpad). Dissociation constants of GluA1-Fab and Mut-Fab and the maximum response were evaluated using SigmaPlot (Systat Software Inc.).

#### Immunofluorescence {#sec4.4.4.2}

cDNA constructs of the mouse GluA1 (*flip* isoform, UniProt ID: [P23818](uniprotkb:P23818){#intref0265}, residues: 19-907), rat GluA2 (identical to the mouse ortholog in the extracellular regions, *flip* isoform, UniProt ID: [P19491](uniprotkb:P19491){#intref0270}, residues: 22-883), mouse GluA3 (*flip* isoform, UniProt ID: [Q9Z2W9](uniprotkb:Q9Z2W9){#intref0275}, residues: 24-888) and mouse GluA4 (*flip* isoform, UniProt ID: [Q9Z2W8](uniprotkb:Q9Z2W8){#intref0280}, residues 21-902) subunits were cloned into the pHLsec vector ([@bib3]) between the AgeI and the XhoI sites. N-terminal HA-tag (YPYDVPDYA, for GluA1, GluA3 and GluA4) or FLAG-tag (DYKDDDDK, for GluA2) sequences were present immediately upstream of the first mature polypeptide residues. Plasmids were transfected into HEK293T cells using Lipofectamine 2000 (Thermo Fisher Scientific, Cat. 11668019). One day post transfection, cells were incubated with 5μM GluA1-Fab, rabbit anti-HA (Sigma-Aldrich, Cat. H6908, 10 μg/ml) or rabbit anti-Flag (Sigma-Aldrich, Cat. F7425, 5 μg/ml) antibodies in tissue culture medium, on ice, for one hour. Afterward, cells were washed with Dulbecco's phosphate-buffered saline (DPBS) with Ca^2+^ and Mg^2+^ (Sigma-Aldrich, Cat. D8662), and then fixed for 5 minutes at room temperature with 3% paraformaldehyde (Sigma-Aldrich, Cat. P6148). Cells were then blocked with antibody buffer (150mM NaCl; 50mM Tris pH 7.4; 100mM L-lysine; 1% BSA) for 30 minutes at room temperature, and incubated with secondary antibodies, goat anti-mouse IgG (Fab specific)-FITC (Sigma-Aldrich, Cat. F4018, dilution 1:750) or Alexa Fluor 647 goat anti-rabbit IgG (H+L) (Invitrogen, CAt. A21245, 5 μg/ml) in antibody buffer supplemented with 10% goat serum, for 1 hour at room temperature. Unbound antibodies were removed by washing with DPBS (three times, 5 minutes each, at room temperature), with one final wash containing Hoechst 33342 nuclear stain (stock 10mg/ml, use 1:100,000, Sigma-Aldrich, Cat. B2261). Immunofluorescence was detected using a Leica TCS SP8 WLL Confocal SMD microscope and images were processed in Fiji (ImageJ).

#### Treating RGC Neurons with Fab {#sec4.4.4.3}

2.5 μM final concentration of GluA1-Fab or Mut-Fab were used to treat RGCs.

#### Treating RGC Neurons with Purified Alexa488-Tagged NP1 and Fab {#sec4.4.4.4}

RGCs were treated with NP1 at a final concentration of 0.4 μg/ml (0.008 μM assuming M.W. of 47 kDa) together with 2.5 μM final concentration of GluA1-Fab or Mut-Fab for 24 hours prior to fixation and imaging. 24 hours later cell tracker red (Life Tech Cat. C34552) was added to the cell culture media (see surface immunostaining of RGCs) for 30 min at 37C, followed by 3 washes with DPBS and 5 min fixation with 4% PFA at room temp. Then coverslips were washed 3 times with PBS and mounted on slides and imaged as described in the cell surface immunostaining section (see below).

### Preparation of Astrocyte Conditioned Media (ACM) {#sec4.4.5}

Astrocytes were plated on 15 cm tissue culture plates and allowed to reach ∼90% confluency. Cells were washed 3X times with warm DPBS to remove serum containing cell culture media and placed in a low protein conditioning media containing (50% DMEM, 50% Neurobasal media; Penicillin-Streptomycin; Glutamax and sodium pyruvate). Astrocytes were incubated for 3-5 days, after which media containing the secreted proteins was collected and concentrated 50-fold using 10 kDa cutoff concentrators (Sartorius Cat. 14558502). Protein concentration was measured using the Bradford method. The amount of ACM fed to RGCs was 50 μg/ml.

### Western Blot {#sec4.4.6}

Samples were heated in reducing loading dye (Thermo Cat. 39000) for 45 min at 55C. Samples were resolved on 4%--12% bis-tris or bolt gels (Invitrogen Cat. NW04120) for 30-40 min at 150-200V. Proteins were transferred to PVDF membranes at 100V for 1 hr, then blocked in 1% casein (Biorad Cat. 1610782) in TBS (Bioworld Cat. 105300272) blocking buffer for 1 hr at room temp on a shaker. Primary antibodies were applied overnight at 4C diluted in blocking buffer. The next day, membranes were washed 3X 10 min with TBS-0.1%Tween and secondary antibody conjugated to Alexa fluor 680 was applied for 2 hr at room temp. Bands were visualized using the Odyssey Infrared Imager (Li-Cor) and band intensity analyzed using the Image Studio software (Li-Cor).

### RNA Analysis from RGCs *In Vitro* {#sec4.4.7}

#### Microarray {#sec4.4.7.1}

For microarray experiments RGCs were grown in 6-well plates at a density of 250,000 cells/well, 2 wells were pooled per experimental condition. RGCs were treated with Gpc4 or TSP1 for 12 hours before collection of RNA. RNA was harvested and purified using the QIAGEN RNeasy mini kit with on column DNA digestion (QIAGEN Cat. 74104), following manufacturer instructions. RNA was processed, hybridized and scanned following manufacturer instructions for Affymetrix Rat Genome 230 2.0 arrays (Affymetrix Cat. 900505). The experiment was repeated on 2 separate RGC cultures. Data was processed and analyzed using Affymetrix Expression Console software. Raw data has been deposited at GEO. Full data is provided in [Table S1](#mmc2){ref-type="supplementary-material"}.

#### qRT-PCR {#sec4.4.7.2}

For qPCR experiments RGCs were grown in 48 well plates, 3 wells were pooled per experimental condition. RGCs were treated with Gpc4 for the time indicated in the text (1 hour, 4 hours, 12 hours or 18 hours). RGCs were then lysed and cDNA prepared using the Cell-to-Ct kit (Life Tech Cat. 4402954). Reverse transcription reaction contained the following steps: 1 cycle at 37°C for 60 minutes, 1 cycle at 95°C for 5 min. The cDNA was then used for the qPCR reaction. Rat Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a control housekeeping gene to normalize the Ct values obtained for the candidate gene primers. The qPCR reaction was performed using the power SYBR green PCR master mix (Life Tech Cat. 4402954) and contained: one enzyme activation step at 95°C for 10 minutes, 40 PCR cycles at 95°C for 15 s and at 60°C for one minute. Data was analyzed using the SDS 2.4 software (Applied Biosystems).

### Immunostaining RGCs *In Vitro* {#sec4.4.8}

#### Treatment of RGCs with Synaptogenic Factors {#sec4.4.8.1}

RGCs were treated with purified proteins or ACM or astrocyte inserts for 6 days to ensure maximal effect on synapse formation and GluA1 clustering, unless stated otherwise in the text. In each experiment the control group is RGCs grown in cell culture media alone.

#### Treatment of RGCs with Transcription Inhibitor {#sec4.4.8.2}

RGCs were treated with Actinomycin D (ActD) (Fisher Cat. 11805017) for 4 or 12 hours. Actinomycin D concentration was 1 μg/ml.

#### Knockdown of NP1 in RGCs Using siRNA {#sec4.4.8.3}

siRNA against rat NP1 was purchased from Dharmacon (set of 4 ON-target plus siRNA smart pool, Cat. LQ-098200-02-0002). ON-TARGETplus Non-targeting Pool (Cat. D-001810-10-05) was used as control and labeled siControl. RGCs at DIV 7-8 were transfected with siNP1 or siControl together with GFP to mark transfected cells using lipofectamine 2000 reagent according to manufacturer instructions. The next day cells were treated with Gpc4 or vehicle for additional 6 days (as above).

#### Cell Surface iImmunostaining {#sec4.4.8.4}

To visualize cell surface proteins without permeabilizing the cells, RGCs were incubated with primary antibody along with fluorescent cell tracker red (Life Tech Cat. C34552) to visualize cell processes for 30 min at 37C in cell culture incubator. After that, cells were washed 3 times with 34C DPBS, fixed for exactly 5 min at room temp with 34C 4% PFA (EMS Cat. 50980487), and blocked with antibody buffer (150 mM NaCl; 50 mM Tris; 100 mM L-lysine; 1% BSA; pH 7.4) supplemented with 50% heat inactivated normal goat serum (Life tech Cat. 16210072) for 30 min at room temp. The short fixation time as well as absence of Triton X-100 from the blocking buffer were necessary to prevent permeabilization of the cells. Finally, secondary antibody conjugated to Alexa fluor 488 diluted in antibody buffer with 10% goat serum was applied for 1 hr at room temp. Coverslips were washed 3x with PBS and mounted using the SlowFade Gold with DAPI mounting media (Life Tech Cat. S36939) on glass slides (Fisher Cat. 125442) and sealed with clear nail polish. Mounted coverslips were imaged using fluorescent microscope (Ziess; Axio Imager.Z2) at 63X magnification. 16 bit images at 1388 X 1040 pixels were acquired using AxioCam HR3 camera (Zeiss). All experimental groups per given experiment were imaged on the same day using set exposure as determined for the positive control group in each experiment (RGCs+ astrocytes; RGCs + ACM; RGCs + Gpc4; RGCs +TSP1; RGCs siControl+Gpc4). Cells were detected using the cell tracker red channel, and an image of the cell surface puncta was obtained. 20-30 cells across 3 coverslips were imaged for each group. For GluA1 surface staining experiments images were analyzed using the Integrated Morphometry application of the Metamorph software (Molecular devices). For each cell, a region of interest containing the cell body and proximal dendrites was outlined and cropped. Positive puncta were determined by manually thresholding the GluA1 channel, then the number of puncta within that region was counted. All cells were thresholded in the same way. For NP1 surface staining, analysis was performed using the Puncta Analyzer plugin in ImageJ. Similarly to GluA1 analysis, a region of interest was cropped, and then number of puncta counted for each cell. Each experiment was performed at least 3 times using different RGC preps.

#### Synaptic Staining {#sec4.4.8.5}

To visualize pre and post synaptic compartments RGCs were washed with 34C DPBS, then fixed at room temp with 4% PFA (EMS Cat. 50980487) for 10 min. Cells were then washed 3 times with PBS and blocked and permeabilized in antibody buffer (150 mM NaCl; 50 mM Tris; 100 mM L-lysine; 1% BSA; pH 7.4) supplemented with 50% heat inactivated normal goat serum (Life tech Cat. 16210072) and 0.2% Triton X-100 (Sigma Cat. T9284) for 30 min at room temp. Primary antibody was applied overnight at 4C diluted in antibody buffer with 10% goat serum. The next day, cells were washed 3 times with PBS and secondary antibody conjugated to Alexa fluor was applied for 1 hr at room temp. Coverslips were washed 3x with PBS and mounted using the SlowFade Gold with DAPI mounting media (Life Tech Cat. S36939) on glass slides (Fisher Cat. 125442) and sealed with clear nail polish. Mounted coverslips were imaged using fluorescent microscope (Ziess; Axio Imager.Z2) at 63X magnification. 16 bit images at 1388 X 1040 pixels were acquired using AxioCam HR3 camera (Zeiss). All experimental groups per given experiment were imaged on the same day using set exposure as determined for the positive control group in each experiment (RGCs+ astrocytes; RGCs + ACM; RGCs + Gpc4; RGCs +TSP1; RGCs siControl+Gpc4). Cells were detected using the DAPI channel, and image of pre and postsynaptic puncta was obtained for each cell. For each group 20-30 cells across 3 coverslips were imaged. Images were analyzed using the Puncta Analyzer plugin of ImageJ as described ([@bib2]). For each cell, a region of interest was determined as a circle containing the cell body and proximal dendrites. Positive pre and post synaptic puncta were determined by thresholding each individual channel, and a synapse was then calculated as the colocalization of pre and post synaptic puncta. All cells were thresholded in the same way. All experiments were repeated at least 3 times using different RGC preps.

#### Imaging and Analysis of Synapses within Transfected Axons in RGCs {#sec4.4.8.6}

For experiments testing the number of synapses which colocalize with axons expressing RPTPs ([Figure 3](#fig3){ref-type="fig"}), RGCs were transfected with cDNA expressing an HA-tagged RPTP of interest at DIV 7 using lipofectamine 2000. GFP transfection was used as a control condition. The next day RGCs were treated with purified His-Gpc4 for 6 days to induce synapse formation. RGCs were then immunostained with antibodies against pre- and post-synaptic markers, as well as an antibody against the HA tag to visualize the axons overexpressing the RPTP. Cells were imaged using fluorescent microscope (Ziess; Axio Imager.Z2) at 63X magnification. 16 bit images at 1388 X 1040 pixels were acquired using AxioCam HR3 camera (Zeiss). Expressing axons were visualized in the green channel, and were selected by morphology as long processes wrapping around a non-expressing cell body (the non-expressing cell body did not show staining in the green channel). For each cell a z stack image was taken (optical slice 0.5 um) to cover the entire axon wrapped around the cell. All experimental groups per given experiment were imaged on the same day using set exposure as determined for the positive control group in each experiment (GFP expressing RGCs + Gpc4). 3D z stack images were analyzed using Imaris software (Bitplane). The GFP or RPTP expressing axon was selected based on intensity in the green channel and cropped. Pre and post synaptic puncta were selected based on size and intensity by thresholding each image in the same way. Then number of synapses (the amount of colocalized pre and post synaptic puncta) was counted for each cell. Finally, only the synapses which overlapped with the axon area were selected for each cell. To account for the differences in size of analyzed axonal area, the total volume of the axon was calculated for each cell. No significant difference between the total axonal volumes was found between the experimental groups (data not shown). Example images in [Figure 3](#fig3){ref-type="fig"} and [Figure S3](#mmc1){ref-type="supplementary-material"}A show maximal intensity projection images. All experiments were repeated at least 3 times using different RGC preps.

### Mouse Brain Tissue Preparation and Immunostaining {#sec4.4.9}

#### Tissue Collection and Processing {#sec4.4.9.1}

Mice were anaesthetized by I.P. injection of 100 mg/kg Ketamine (Victor Medical Company)/20 mg/kg Xylazine (Anased) mix and transcardially perfused with PBS. To obtain fresh frozen tissue used for RNAscope *in situ* experiments and immunostaining, brains were removed and immediately embedded in OCT media (Scigen Cat. 4583), frozen in dry ice-ethanol slurry solution, and stored at −80C until use. To obtain fixed tissue used for immunostaining in [Figures 7](#fig7){ref-type="fig"}A, [8](#fig8){ref-type="fig"}, [S6](#mmc1){ref-type="supplementary-material"}C, [S7](#mmc1){ref-type="supplementary-material"}B, and S7D--S7F, PBS perfusion was immediately followed by perfusing the mice with 4% PFA. Brains and/or eyes were removed and incubated in 4% PFA overnight at 4C, then washed 3X 5 min with PBS, and cryoprotected in 30% sucrose for 2-3 days, before being embedded in TFM media (General data healthcare Cat. TFM-5), frozen in dry ice-ethanol slurry solution, and stored at −80C until use. Brains were sectioned using a cryostat (Hacker Industries OTF5000) in sagittal or coronal orientations depending on experimental needs at a slice thickness of 16 μm. Eyes were sectioned through the lens-optic nerve axis at a slice thickness of 16 μm. Sections were mounted on Superfrost plus slides (Fisher Cat. 1255015).

#### Immunostaining and Imaging in Mouse Brain Tissue {#sec4.4.9.2}

Immunostaining of fresh frozen tissue was performed immediately following brain sectioning. Sections were fixed for 8 min with methanol at −20C, then washed with PBS (3X 5 min) and fixed for 8 min with 4% PFA at room temp, then washed with PBS (3X 5 min). Sections were then blocked for 1 hr at room temp in blocking buffer containing antibody buffer (100 mM L-lysine and 0.3% Triton X-100 in PBS) supplemented with 10% heat inactivated normal goat serum. Primary antibodies diluted in antibody buffer with 5% goat serum were incubated overnight at 4C. The next day sections were washed 3X 5 min with PBS with 0.2% Triton X-100 and secondary antibodies conjugated to Alexa fluor were applied for 2 hr at room temp. Slides were mounted with the SlowFade Gold with DAPI mounting media (Life Tech Cat. S36939), covered with 1.5 glass coverslip (Fisher Cat. 12544E) and sealed with clear nail polish. Slides were imaged using Zeiss LSM 780 confocal microscope at 63X magnification. Experiments shown in [Figures 6](#fig6){ref-type="fig"}J--6M slides were imaged using Zeiss LSM 880 confocal microscope using same magnification and imaging parameters. All imaging of a given experiment was obtained on the same day (WT and KO), with set exposure as determined for the control group (WT genotype). For each section a 1420 X 1420 pixel 3 μm thick z stack image was obtained (optical slice 0.33 μm; 9 slices per 3 μm stack). 3D z stack images were analyzed using Imaris software (Bitplane). Images were background subtracted in the same way and positive puncta of NP1, RPTPδ or VGlut2 were selected by size and intensity by thresholding the images in the same way for each section. Then colocalization between NP1 and VGlut2 or RPTPδ and VGlut2 was calculated. Puncta were considered colocalized if the distance between them was ≤ 0.5 μm. Number of colocalized puncta was obtained and compared between the experimental groups. A minimum of 3 sections per mouse were imaged for each brain region, and the experiment repeated in at least 3 WT and KO littermate pairs. Example images show single z plane from the same location in the stack for both genotypes.

For immunostaining of PFA fixed tissue, following cryosectioning, the slides containing the sections were blocked for 1 hr at room temp in blocking buffer containing antibody buffer (100 mM L-lysine and 0.3% Triton X-100 in PBS) supplemented with 10% heat inactivated normal goat serum. Primary antibodies diluted in antibody buffer with 5% goat serum were incubated overnight at 4C. The next day slides were washed 3X 5 min with PBS with 0.2% Triton X-100 and secondary antibodies conjugated to Alexa fluor were applied for 2 hr at room temp. Slides were mounted with the SlowFade Gold with DAPI mounting media (Life Tech Cat. S36939), covered with 1.5 glass coverslip (Fisher Cat. 12544E) and sealed with clear nail polish. For experiments shown in [Figures 7](#fig7){ref-type="fig"}A, [S6](#mmc1){ref-type="supplementary-material"}C, [S7](#mmc1){ref-type="supplementary-material"}B, and S7D--S7F slides were imaged with fluorescent microscope (Zeiss Axio Imager.Z2) using the Apotome.2 module (Zeiss) at 10x, 20x or 40x magnifications. 16 bit images at 1388 X 1040 pixels were acquired using AxioCam HR3 camera (Zeiss). Z stack images (optical slice 1 μm; 5-7 μm stack) were obtained for each image. Set exposure was used when comparing WT and KO mice per given experiment. Example images show maximal intensity projection images.

Experiments testing RORα cre expression pattern in thalamo-cortical axons ([Figures S7](#mmc1){ref-type="supplementary-material"}E and S7F, lower panels) were imaged using Zeiss LSM 780 confocal microscope at 63X magnification. For each section a 1420 X 1420 pixel 3 μm thick z stack image was obtained (optical slice 0.33 μm; 9 slices per 3 μm stack).

For experiments described in [Figure 8](#fig8){ref-type="fig"} slides were imaged using Zeiss LSM 880 confocal microscope at 63X magnification. For each section a 1420 X 1420 pixel 3 μm thick z stack image was obtained (optical slice 0.33 μm; 9 slices per 3 μm stack). Set exposure was used when comparing WT and KO mice per given experiment. Images were analyzed using the Imaris software (Bitplane) in the same way as described above for fresh frozen NP1-VGlut2 colocalization. Example images show single z plane from the same location in the stack for both genotypes.

#### RNAscope *In Situ* Hybridization {#sec4.4.9.3}

RNAscope *in situ* hybridization experiments were performed according to manufacturer's instructions for fresh frozen tissue. The chromogenic assay shown in [Figures 5](#fig5){ref-type="fig"}A, 5B, [7](#fig7){ref-type="fig"}J, and [S4](#mmc1){ref-type="supplementary-material"}A was performed using the RNAscope 2.5 HD---BROWN Manual Assay kit (Acdbio Cat. 322300). Briefly, fresh frozen mouse brain tissue was sectioned at 16 μm, mounted on Superfrost plus slides (Fisher Cat. 1255015) and dried at −20C for 1 hr. Slides were stored at −80C until use. Slides were fixed for 15 min at 4C with 4% PFA, and then sequentially dehydrated with 50, 70 and 100% ethanol. Sections were then permeabilized with pretreatment reagent for 10-20 min (Protease plus Cat. 322330) and specific probe was applied to each slide. Slides were incubated with the probes for 2 hr at 40C in the hybridization oven (HybEZ hybridization system; ACDbio). After that, 6 amplification steps and 1 detection step were performed as per manufacturer instruction, and mRNA signal was detected with Dab reagent (ACDbio Cat. 322300). DAPI (1:1000; Millipore Cat 5.08741.0001) was applied to visualize the cell nuclei. Finally, slides were dehydrated again with sequential ethanol washes and cleared with xylene. Slides were mounted with Cytoseal mounting media (Thermo Cat. 8312-4) covered with 1.5 glass coverslip (Fisher Cat. 12544E) and left to dry overnight at room temp. Slides were imaged using the Axio Imager.Z2 fluorescent microscope (Zeiss). A 16 bit 1388 X 1040 pixel images were acquired using AxioCam HR3 camera (Zeiss). The Dab signal was imaged using the brightfield settings at 10x magnification; cell nuclei were imaged using the DAPI channel. Set exposure was used when comparing signal between WT and KO mice for a given experiment.

#### Fluorescent RNAscope *In Situ* Hybridization {#sec4.4.9.4}

The fluorescent *in situ* assay shown in [Figures 5](#fig5){ref-type="fig"}C, 5E, [6](#fig6){ref-type="fig"}I, [S4](#mmc1){ref-type="supplementary-material"}B, S4C, and [S7](#mmc1){ref-type="supplementary-material"}G--S7I was performed using the RNAscope 2.5 HD---multiplex fluorescent Manual Assay kit (ACDbio Cat. 320850). In this assay tissue was prepared and pretreated in the same way as in the chromogenic assay (see above). After incubation with target probes, 3 amplification steps and 1 detection step were performed following manufacturer instructions. Slides were mounted using the SlowFade Gold with DAPI mounting media (Life Tech Cat. S36939) covered with 1.5 glass coverslip (Fisher Cat. 12544E) and sealed with clear nail polish. Slides were imaged using the Axio Imager.Z2 fluorescent microscope (Zeiss). A 16 bit 1388 X 1040 pixel images were acquired using AxioCam HR3 camera (Zeiss). Fluorescent signal was imaged at 20x magnification using the Apotome.2 module (Zeiss). Z stack images (optical slice 1 μm) were obtained for each image. Set exposure was used when comparing signal between WT and KO mice for a given experiment. For cell type specific expression quantification experiments shown in [Figures 5](#fig5){ref-type="fig"}C--5E slides were imaged using the Zeiss LSM 710 confocal microscope at 20X magnification. 16 bit images at 0.16 μm/pixel were generated. A z stack (optical slice 1 μm, 6 slices total) was obtained for each image. Example images show maximal intensity projections for each group.

#### Analysis and Quantification of Cell-Specific Expression of Gpc4 mRNA {#sec4.4.9.5}

For analysis shown in [Figures 5](#fig5){ref-type="fig"}C--5E 3 mice were used for each brain region, and for each mouse 3 brain sections were processed, imaged and analyzed. For analysis 2 regions of interest (ROI) of 130X130 μm were selected and cropped from each image. The images were thresholded to reveal positive signal in the same way for each image and the number of cells was then manually counted using the cell counter option of Fiji (ImageJ). The number of Gpc4 expressing cells was counted as well as the number of cells positive for both Gpc4 and Aldh1l1 (astrocyte specific expression) or Gpc4 and Tubb3 positive cells (neuronal specific expression). Finally a fraction of Gpc4+Aldh1l1 positive cells was plotted out of total Gpc4 expressing cells and compared to the fraction of Gpc4+Tubb3 positive cells.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

All data is presented as mean ± s.e.m. Statistical analysis was performed using Sigma plot software (Systat software inc.). Multiple group comparisons were done using one-way Analysis of Variance (ANOVA) with post hoc Dunn's or Dunnet's tests. Pairwise comparisons were done by t test. When data did not pass normal distribution test, multiple comparisons were done by Kruskal-Wallis ANOVA on ranks and pairwise comparisons were done with Mann-Whitney Rank Sum test. P value ≤ 0.05 was considered statistically significant. The sample sizes, statistical tests used and significance are presented in each figure legend.

Data and Software Availability {#sec4.6}
------------------------------

The microarray data have been deposited in GEO: [GSE86595](ncbi-geo:GSE86595){#intref0285}.
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